SK4182002A3 - Compounds for the treatment of ischemia - Google Patents

Compounds for the treatment of ischemia Download PDF

Info

Publication number: SK4182002A3
Authority: SK; Slovakia
Prior art keywords: alkyl; carbon atoms; compounds; guanidine; pyrazole
Prior art date: 1999-09-30

Application number

SK418-2002A

Other languages

English (en)

Slovak (sk)

Inventor

Hiroko Masamune

Michael Paul Deninno

Robert William Scott

Original Assignee

Pfizer Prod Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-09-30

Filing date

2000-09-22

Publication date

2003-04-01

2000-09-22 Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc

2003-04-01 Publication of SK4182002A3 publication Critical patent/SK4182002A3/sk

Links

208000028867 ischemia Diseases 0.000 title claims abstract description 30
150000001875 compounds Chemical class 0.000 title claims description 394
238000000034 method Methods 0.000 claims abstract description 207
206010021143 Hypoxia Diseases 0.000 claims abstract description 32
230000000451 tissue damage Effects 0.000 claims abstract description 26
231100000827 tissue damage Toxicity 0.000 claims abstract description 26
230000007954 hypoxia Effects 0.000 claims abstract description 17
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 15
-1 oxy, methylene Chemical group 0.000 claims description 400
125000004432 carbon atom Chemical group C* 0.000 claims description 193
125000000217 alkyl group Chemical group 0.000 claims description 172
229910052757 nitrogen Inorganic materials 0.000 claims description 160
150000003839 salts Chemical class 0.000 claims description 113
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 88
229910052739 hydrogen Inorganic materials 0.000 claims description 86
239000001257 hydrogen Substances 0.000 claims description 86
229920006395 saturated elastomer Polymers 0.000 claims description 86
239000000203 mixture Substances 0.000 claims description 75
229940002612 prodrug Drugs 0.000 claims description 69
239000000651 prodrug Substances 0.000 claims description 69
125000003545 alkoxy group Chemical group 0.000 claims description 67
125000000753 cycloalkyl group Chemical group 0.000 claims description 61
229910052760 oxygen Inorganic materials 0.000 claims description 61
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 60
239000001301 oxygen Substances 0.000 claims description 60
229910052736 halogen Inorganic materials 0.000 claims description 59
150000002367 halogens Chemical class 0.000 claims description 56
ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 claims description 54
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 51
229910052717 sulfur Inorganic materials 0.000 claims description 51
239000011593 sulfur Chemical group 0.000 claims description 51
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 50
125000005842 heteroatom Chemical group 0.000 claims description 48
239000003112 inhibitor Substances 0.000 claims description 46
125000001424 substituent group Chemical group 0.000 claims description 46
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 44
150000002431 hydrogen Chemical class 0.000 claims description 44
210000001519 tissue Anatomy 0.000 claims description 43
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 43
125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 38
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 34
241000124008 Mammalia Species 0.000 claims description 33
210000002216 heart Anatomy 0.000 claims description 33
SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 claims description 32
125000004433 nitrogen atom Chemical group N* 0.000 claims description 29
239000000460 chlorine Substances 0.000 claims description 28
CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 claims description 27
SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 claims description 27
125000004093 cyano group Chemical group *C#N 0.000 claims description 26
OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 claims description 25
229910052801 chlorine Inorganic materials 0.000 claims description 23
125000002541 furyl group Chemical group 0.000 claims description 23
125000000440 benzylamino group Chemical group [H]N(*)C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 22
239000002552 dosage form Substances 0.000 claims description 22
125000005699 methyleneoxy group Chemical group [H]C([H])([*:1])O[*:2] 0.000 claims description 22
125000002619 bicyclic group Chemical group 0.000 claims description 21
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 21
125000004545 purin-9-yl group Chemical group N1=CN=C2N(C=NC2=C1)* 0.000 claims description 21
125000002757 morpholinyl group Chemical group 0.000 claims description 20
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 20
125000003386 piperidinyl group Chemical group 0.000 claims description 20
238000001356 surgical procedure Methods 0.000 claims description 20
239000003937 drug carrier Substances 0.000 claims description 19
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 18
239000003795 chemical substances by application Substances 0.000 claims description 18
125000000335 thiazolyl group Chemical group 0.000 claims description 18
125000000000 cycloalkoxy group Chemical group 0.000 claims description 17
125000004076 pyridyl group Chemical group 0.000 claims description 17
125000000719 pyrrolidinyl group Chemical group 0.000 claims description 17
WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 16
125000004043 oxo group Chemical group O=* 0.000 claims description 16
HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 claims description 15
125000001309 chloro group Chemical group Cl* 0.000 claims description 15
239000003085 diluting agent Substances 0.000 claims description 15
125000002534 ethynyl group Chemical group [H]C#C* 0.000 claims description 15
239000003981 vehicle Substances 0.000 claims description 15
125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims description 15
125000000027 (C1-C10) alkoxy group Chemical group 0.000 claims description 14
239000002126 C01EB10 - Adenosine Substances 0.000 claims description 14
229960005305 adenosine Drugs 0.000 claims description 14
239000002327 cardiovascular agent Substances 0.000 claims description 14
229940125692 cardiovascular agent Drugs 0.000 claims description 14
125000000842 isoxazolyl group Chemical group 0.000 claims description 14
MGJXBDMLVWIYOQ-UHFFFAOYSA-N methylazanide Chemical compound [NH-]C MGJXBDMLVWIYOQ-UHFFFAOYSA-N 0.000 claims description 14
125000002971 oxazolyl group Chemical group 0.000 claims description 14
125000004193 piperazinyl group Chemical group 0.000 claims description 14
230000001225 therapeutic effect Effects 0.000 claims description 13
125000000008 (C1-C10) alkyl group Chemical group 0.000 claims description 12
239000012190 activator Substances 0.000 claims description 12
125000001153 fluoro group Chemical group F* 0.000 claims description 12
210000004185 liver Anatomy 0.000 claims description 12
125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 claims description 12
210000004556 brain Anatomy 0.000 claims description 11
125000001786 isothiazolyl group Chemical group 0.000 claims description 11
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 11
125000000714 pyrimidinyl group Chemical group 0.000 claims description 11
239000011734 sodium Substances 0.000 claims description 11
125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims description 10
102100030980 Sodium/hydrogen exchanger 1 Human genes 0.000 claims description 10
108010093115 growth factor-activatable Na-H exchanger NHE-1 Proteins 0.000 claims description 10
125000003226 pyrazolyl group Chemical group 0.000 claims description 10
125000002098 pyridazinyl group Chemical group 0.000 claims description 10
125000001544 thienyl group Chemical group 0.000 claims description 10
125000004760 (C1-C4) alkylsulfonylamino group Chemical group 0.000 claims description 9
125000003373 pyrazinyl group Chemical group 0.000 claims description 9
150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 8
239000001103 potassium chloride Substances 0.000 claims description 8
235000011164 potassium chloride Nutrition 0.000 claims description 8
125000000168 pyrrolyl group Chemical group 0.000 claims description 8
125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 7
125000004504 1,2,4-oxadiazolyl group Chemical group 0.000 claims description 7
125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims description 7
125000002393 azetidinyl group Chemical group 0.000 claims description 7
239000003379 purinergic P1 receptor agonist Substances 0.000 claims description 7
125000004149 thio group Chemical group *S* 0.000 claims description 7
229940043355 kinase inhibitor Drugs 0.000 claims description 6
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 6
125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 6
125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 5
239000011575 calcium Substances 0.000 claims description 5
125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 claims description 5
125000001624 naphthyl group Chemical group 0.000 claims description 5
125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 5
239000003909 protein kinase inhibitor Substances 0.000 claims description 5
230000002537 thrombolytic effect Effects 0.000 claims description 5
125000006274 (C1-C3)alkoxy group Chemical group 0.000 claims description 4
125000004209 (C1-C8) alkyl group Chemical group 0.000 claims description 4
125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims description 4
125000004514 1,2,4-thiadiazolyl group Chemical group 0.000 claims description 4
239000005541 ACE inhibitor Substances 0.000 claims description 4
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims description 4
229940123208 Biguanide Drugs 0.000 claims description 4
229940127291 Calcium channel antagonist Drugs 0.000 claims description 4
229910002651 NO3 Inorganic materials 0.000 claims description 4
NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 claims description 4
102000012751 Pyruvate Dehydrogenase Complex Human genes 0.000 claims description 4
108010090051 Pyruvate Dehydrogenase Complex Proteins 0.000 claims description 4
229960001138 acetylsalicylic acid Drugs 0.000 claims description 4
125000004414 alkyl thio group Chemical group 0.000 claims description 4
229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims description 4
239000005557 antagonist Substances 0.000 claims description 4
125000005605 benzo group Chemical group 0.000 claims description 4
239000002876 beta blocker Substances 0.000 claims description 4
229940097320 beta blocking agent Drugs 0.000 claims description 4
239000000480 calcium channel blocker Substances 0.000 claims description 4
125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 4
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 4
239000002934 diuretic Substances 0.000 claims description 4
125000004005 formimidoyl group Chemical group [H]\N=C(/[H])* 0.000 claims description 4
229930182470 glycoside Natural products 0.000 claims description 4
150000002338 glycosides Chemical class 0.000 claims description 4
125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims description 4
210000000936 intestine Anatomy 0.000 claims description 4
210000003734 kidney Anatomy 0.000 claims description 4
210000004072 lung Anatomy 0.000 claims description 4
XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 claims description 4
229960003105 metformin Drugs 0.000 claims description 4
230000003647 oxidation Effects 0.000 claims description 4
238000007254 oxidation reaction Methods 0.000 claims description 4
230000036961 partial effect Effects 0.000 claims description 4
239000008024 pharmaceutical diluent Substances 0.000 claims description 4
IENZQIKPVFGBNW-UHFFFAOYSA-N prazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1=CC=CO1 IENZQIKPVFGBNW-UHFFFAOYSA-N 0.000 claims description 4
229960001289 prazosin Drugs 0.000 claims description 4
125000005493 quinolyl group Chemical group 0.000 claims description 4
210000001525 retina Anatomy 0.000 claims description 4
210000002027 skeletal muscle Anatomy 0.000 claims description 4
125000003831 tetrazolyl group Chemical group 0.000 claims description 4
125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 3
125000006555 (C3-C5) cycloalkyl group Chemical group 0.000 claims description 3
JVGJINYQXKIBDT-UHFFFAOYSA-N 1-(2-bromophenyl)-5-cyclopropyl-n-(diaminomethylidene)pyrazole-4-carboxamide Chemical compound NC(=N)NC(=O)C=1C=NN(C=2C(=CC=CC=2)Br)C=1C1CC1 JVGJINYQXKIBDT-UHFFFAOYSA-N 0.000 claims description 3
DZXZXYVVTHIODU-UHFFFAOYSA-N 1-(2-chloro-5-methoxyphenyl)-5-cyclopropyl-n-(diaminomethylidene)pyrazole-4-carboxamide Chemical compound COC1=CC=C(Cl)C(N2C(=C(C(=O)NC(N)=N)C=N2)C2CC2)=C1 DZXZXYVVTHIODU-UHFFFAOYSA-N 0.000 claims description 3
KTMBRLHJWLVWJN-UHFFFAOYSA-N 1-(2-chloro-5-methylsulfonylphenyl)-5-cyclopropyl-n-(diaminomethylidene)pyrazole-4-carboxamide Chemical compound CS(=O)(=O)C1=CC=C(Cl)C(N2C(=C(C(=O)NC(N)=N)C=N2)C2CC2)=C1 KTMBRLHJWLVWJN-UHFFFAOYSA-N 0.000 claims description 3
BINSRSZWKJTYQD-UHFFFAOYSA-N 1-(2-chloro-5-sulfamoylphenyl)-5-cyclopropyl-n-(diaminomethylidene)pyrazole-4-carboxamide Chemical compound NC(=N)NC(=O)C=1C=NN(C=2C(=CC=C(C=2)S(N)(=O)=O)Cl)C=1C1CC1 BINSRSZWKJTYQD-UHFFFAOYSA-N 0.000 claims description 3
OBARLXYWADULRB-UHFFFAOYSA-N 1-(2-chlorophenyl)-5-cyclopropyl-n-(diaminomethylidene)pyrazole-4-carboxamide Chemical compound NC(=N)NC(=O)C=1C=NN(C=2C(=CC=CC=2)Cl)C=1C1CC1 OBARLXYWADULRB-UHFFFAOYSA-N 0.000 claims description 3
PJRZFTYVWGASFT-UHFFFAOYSA-N 1-(3h-benzimidazol-5-yl)-n-(diaminomethylidene)-5-ethylpyrazole-4-carboxamide Chemical compound CCC1=C(C(=O)NC(N)=N)C=NN1C1=CC=C(N=CN2)C2=C1 PJRZFTYVWGASFT-UHFFFAOYSA-N 0.000 claims description 3
XRJAKWJGDAHTMH-UHFFFAOYSA-N 1-(5-carbamoyl-2-chlorophenyl)-5-cyclopropyl-n-(diaminomethylidene)pyrazole-4-carboxamide Chemical compound NC(=N)NC(=O)C=1C=NN(C=2C(=CC=C(C=2)C(N)=O)Cl)C=1C1CC1 XRJAKWJGDAHTMH-UHFFFAOYSA-N 0.000 claims description 3
HQMDTNPGJUCYMV-UHFFFAOYSA-N 1-[2-chloro-4-(methylsulfamoyl)phenyl]-5-cyclopropyl-n-(diaminomethylidene)pyrazole-4-carboxamide Chemical compound ClC1=CC(S(=O)(=O)NC)=CC=C1N1C(C2CC2)=C(C(=O)NC(N)=N)C=N1 HQMDTNPGJUCYMV-UHFFFAOYSA-N 0.000 claims description 3
QDEGSGKUDYTYJV-UHFFFAOYSA-N 1-[4-chloro-2-(trifluoromethyl)phenyl]-5-cyclopropyl-n-(diaminomethylidene)pyrazole-4-carboxamide Chemical compound NC(=N)NC(=O)C=1C=NN(C=2C(=CC(Cl)=CC=2)C(F)(F)F)C=1C1CC1 QDEGSGKUDYTYJV-UHFFFAOYSA-N 0.000 claims description 3
ZWKXLNHOSNQZLS-UHFFFAOYSA-N 5-cyclopropyl-n-(diaminomethylidene)-1-(1h-indazol-7-yl)pyrazole-4-carboxamide Chemical compound NC(=N)NC(=O)C=1C=NN(C=2C=3NN=CC=3C=CC=2)C=1C1CC1 ZWKXLNHOSNQZLS-UHFFFAOYSA-N 0.000 claims description 3
LGOPZILIFLMNPA-UHFFFAOYSA-N 5-cyclopropyl-n-(diaminomethylidene)-1-(2,3-dichlorophenyl)pyrazole-4-carboxamide Chemical compound NC(=N)NC(=O)C=1C=NN(C=2C(=C(Cl)C=CC=2)Cl)C=1C1CC1 LGOPZILIFLMNPA-UHFFFAOYSA-N 0.000 claims description 3
NVPIIEFYJSAEED-UHFFFAOYSA-N 5-cyclopropyl-n-(diaminomethylidene)-1-(2,5-dichlorophenyl)pyrazole-4-carboxamide Chemical compound NC(=N)NC(=O)C=1C=NN(C=2C(=CC=C(Cl)C=2)Cl)C=1C1CC1 NVPIIEFYJSAEED-UHFFFAOYSA-N 0.000 claims description 3
PTVBGVLITQPZTD-UHFFFAOYSA-N 5-cyclopropyl-n-(diaminomethylidene)-1-(2,6-dichlorophenyl)pyrazole-4-carboxamide Chemical compound NC(=N)NC(=O)C=1C=NN(C=2C(=CC=CC=2Cl)Cl)C=1C1CC1 PTVBGVLITQPZTD-UHFFFAOYSA-N 0.000 claims description 3
HMCQXPJNWHQROJ-UHFFFAOYSA-N 5-cyclopropyl-n-(diaminomethylidene)-1-(2-fluorophenyl)pyrazole-4-carboxamide Chemical compound NC(=N)NC(=O)C=1C=NN(C=2C(=CC=CC=2)F)C=1C1CC1 HMCQXPJNWHQROJ-UHFFFAOYSA-N 0.000 claims description 3
SSQWWXQZCXSTHE-UHFFFAOYSA-N 5-cyclopropyl-n-(diaminomethylidene)-1-[2-fluoro-6-(trifluoromethyl)phenyl]pyrazole-4-carboxamide Chemical compound NC(=N)NC(=O)C=1C=NN(C=2C(=CC=CC=2F)C(F)(F)F)C=1C1CC1 SSQWWXQZCXSTHE-UHFFFAOYSA-N 0.000 claims description 3
DJEYTYIFAGYQSJ-UHFFFAOYSA-N 5-cyclopropyl-n-(diaminomethylidene)-1-[4-fluoro-2-(trifluoromethyl)phenyl]pyrazole-4-carboxamide Chemical compound NC(=N)NC(=O)C=1C=NN(C=2C(=CC(F)=CC=2)C(F)(F)F)C=1C1CC1 DJEYTYIFAGYQSJ-UHFFFAOYSA-N 0.000 claims description 3
YZLNQKMWEXOAPY-UHFFFAOYSA-N 5-cyclopropyl-n-(diaminomethylidene)-1-phenylpyrazole-4-carboxamide Chemical compound NC(=N)NC(=O)C=1C=NN(C=2C=CC=CC=2)C=1C1CC1 YZLNQKMWEXOAPY-UHFFFAOYSA-N 0.000 claims description 3
NQDZNLKMTLAUGA-UHFFFAOYSA-N 5-cyclopropyl-n-(diaminomethylidene)-1-quinolin-4-ylpyrazole-4-carboxamide Chemical compound NC(=N)NC(=O)C=1C=NN(C=2C3=CC=CC=C3N=CC=2)C=1C1CC1 NQDZNLKMTLAUGA-UHFFFAOYSA-N 0.000 claims description 3
GDXBRVCQGGKXJY-UHFFFAOYSA-N 5-cyclopropyl-n-(diaminomethylidene)-1-quinolin-5-ylpyrazole-4-carboxamide Chemical compound NC(N)=NC(=O)C=1C=NN(C=2C3=CC=CN=C3C=CC=2)C=1C1CC1 GDXBRVCQGGKXJY-UHFFFAOYSA-N 0.000 claims description 3
LFOAPSAWYUILCY-UHFFFAOYSA-N 5-cyclopropyl-n-(diaminomethylidene)-1-quinolin-8-ylpyrazole-4-carboxamide Chemical compound NC(=N)NC(=O)C=1C=NN(C=2C3=NC=CC=C3C=CC=2)C=1C1CC1 LFOAPSAWYUILCY-UHFFFAOYSA-N 0.000 claims description 3
AEOBEOJCBAYXBA-UHFFFAOYSA-N A2P5P Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1OP(O)(O)=O AEOBEOJCBAYXBA-UHFFFAOYSA-N 0.000 claims description 3
102000000452 Acetyl-CoA carboxylase Human genes 0.000 claims description 3
108010016219 Acetyl-CoA carboxylase Proteins 0.000 claims description 3
108010018763 Biotin carboxylase Proteins 0.000 claims description 3
101000914947 Bungarus multicinctus Long neurotoxin homolog TA-bm16 Proteins 0.000 claims description 3
102000003960 Ligases Human genes 0.000 claims description 3
108090000364 Ligases Proteins 0.000 claims description 3
102000008299 Nitric Oxide Synthase Human genes 0.000 claims description 3
108010021487 Nitric Oxide Synthase Proteins 0.000 claims description 3
108091026813 Poly(ADPribose) Proteins 0.000 claims description 3
229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 claims description 3
102000003923 Protein Kinase C Human genes 0.000 claims description 3
108090000315 Protein Kinase C Proteins 0.000 claims description 3
235000014113 dietary fatty acids Nutrition 0.000 claims description 3
239000000194 fatty acid Substances 0.000 claims description 3
229930195729 fatty acid Natural products 0.000 claims description 3
150000004665 fatty acids Chemical class 0.000 claims description 3
230000000968 intestinal effect Effects 0.000 claims description 3
DPPAQYSYEWTCPT-UHFFFAOYSA-N n-(diaminomethylidene)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-5-ethylpyrazole-4-carboxamide Chemical compound CCC1=C(C(=O)NC(N)=N)C=NN1C1=CC=C(OCCO2)C2=C1 DPPAQYSYEWTCPT-UHFFFAOYSA-N 0.000 claims description 3
USEQIAAJQHCEER-UHFFFAOYSA-N n-(diaminomethylidene)-5-methyl-1-[2-(trifluoromethyl)phenyl]pyrazole-4-carboxamide Chemical compound CC1=C(C(=O)NC(N)=N)C=NN1C1=CC=CC=C1C(F)(F)F USEQIAAJQHCEER-UHFFFAOYSA-N 0.000 claims description 3
239000002777 nucleoside Substances 0.000 claims description 3
210000000496 pancreas Anatomy 0.000 claims description 3
210000001032 spinal nerve Anatomy 0.000 claims description 3
210000000952 spleen Anatomy 0.000 claims description 3
210000005166 vasculature Anatomy 0.000 claims description 3
125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims description 2
ZJQFENWMXOATQM-UHFFFAOYSA-N 1-(2-chloro-4-methylsulfonylphenyl)-5-cyclopropyl-n-(diaminomethylidene)pyrazole-4-carboxamide Chemical compound ClC1=CC(S(=O)(=O)C)=CC=C1N1C(C2CC2)=C(C(=O)NC(N)=N)C=N1 ZJQFENWMXOATQM-UHFFFAOYSA-N 0.000 claims description 2
FQKVIFIBQBRQEY-UHFFFAOYSA-N 1-(2h-benzotriazol-5-yl)-n-(diaminomethylidene)-5-ethylpyrazole-4-carboxamide Chemical compound CCC1=C(C(=O)NC(N)=N)C=NN1C1=CC=C(NN=N2)C2=C1 FQKVIFIBQBRQEY-UHFFFAOYSA-N 0.000 claims description 2
AWDVOIVMYCOEGE-UHFFFAOYSA-N 1-(3-chloro-2h-indazol-5-yl)-n-(diaminomethylidene)-5-ethylpyrazole-4-carboxamide Chemical compound CCC1=C(C(=O)NC(N)=N)C=NN1C1=CC=C(NN=C2Cl)C2=C1 AWDVOIVMYCOEGE-UHFFFAOYSA-N 0.000 claims description 2
NHFITSUMYNECAK-UHFFFAOYSA-N 1-(3h-benzimidazol-5-yl)-5-cyclopropyl-n-(diaminomethylidene)pyrazole-4-carboxamide Chemical compound NC(=N)NC(=O)C=1C=NN(C=2C=C3NC=NC3=CC=2)C=1C1CC1 NHFITSUMYNECAK-UHFFFAOYSA-N 0.000 claims description 2
RQGPHRVFYWHLQW-UHFFFAOYSA-N 1-[2-chloro-5-(dimethylsulfamoyl)phenyl]-5-cyclopropyl-n-(diaminomethylidene)pyrazole-4-carboxamide Chemical compound CN(C)S(=O)(=O)C1=CC=C(Cl)C(N2C(=C(C(=O)NC(N)=N)C=N2)C2CC2)=C1 RQGPHRVFYWHLQW-UHFFFAOYSA-N 0.000 claims description 2
125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 claims description 2
125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 claims description 2
LFXTUZDNFLZCNR-UHFFFAOYSA-N 5-cyclopropyl-n-(diaminomethylidene)-1-[2-(trifluoromethyl)phenyl]pyrazole-4-carboxamide Chemical compound NC(=N)NC(=O)C=1C=NN(C=2C(=CC=CC=2)C(F)(F)F)C=1C1CC1 LFXTUZDNFLZCNR-UHFFFAOYSA-N 0.000 claims description 2
DUEARGDWUYBBDH-UHFFFAOYSA-N 5-cyclopropyl-n-(diaminomethylidene)-1-isoquinolin-1-ylpyrazole-4-carboxamide Chemical compound NC(=N)NC(=O)C=1C=NN(C=2C3=CC=CC=C3C=CN=2)C=1C1CC1 DUEARGDWUYBBDH-UHFFFAOYSA-N 0.000 claims description 2
125000001931 aliphatic group Chemical group 0.000 claims description 2
125000004466 alkoxycarbonylamino group Chemical group 0.000 claims description 2
125000004457 alkyl amino carbonyl group Chemical group 0.000 claims description 2
125000005169 cycloalkylcarbonylamino group Chemical group 0.000 claims description 2
DIJXCEMJEZJHHT-UHFFFAOYSA-N n-(diaminomethylidene)-5-ethyl-1-(1h-indazol-5-yl)pyrazole-4-carboxamide Chemical compound CCC1=C(C(=O)NC(N)=N)C=NN1C1=CC=C(NN=C2)C2=C1 DIJXCEMJEZJHHT-UHFFFAOYSA-N 0.000 claims description 2
CMULWUTYYYBQQN-UHFFFAOYSA-N n-(diaminomethylidene)-5-ethyl-1-(1h-indazol-6-yl)pyrazole-4-carboxamide Chemical compound CCC1=C(C(=O)NC(N)=N)C=NN1C1=CC=C(C=NN2)C2=C1 CMULWUTYYYBQQN-UHFFFAOYSA-N 0.000 claims description 2
IAPMTJLFQONPMP-UHFFFAOYSA-N n-(diaminomethylidene)-5-ethyl-1-(2-methyl-3h-benzimidazol-5-yl)pyrazole-4-carboxamide Chemical compound CCC1=C(C(=O)NC(N)=N)C=NN1C1=CC=C(N=C(C)N2)C2=C1 IAPMTJLFQONPMP-UHFFFAOYSA-N 0.000 claims description 2
WHYRGUVSHCIYOP-UHFFFAOYSA-N n-(diaminomethylidene)-5-ethyl-1-(3-methylbenzimidazol-5-yl)pyrazole-4-carboxamide Chemical compound CCC1=C(C(=O)NC(N)=N)C=NN1C1=CC=C(N=CN2C)C2=C1 WHYRGUVSHCIYOP-UHFFFAOYSA-N 0.000 claims description 2
VGSVDBBUTFVKKP-UHFFFAOYSA-N n-(diaminomethylidene)-5-ethyl-1-phenylpyrazole-4-carboxamide Chemical compound CCC1=C(C(=O)NC(N)=N)C=NN1C1=CC=CC=C1 VGSVDBBUTFVKKP-UHFFFAOYSA-N 0.000 claims description 2
IJZQRLYNEVAONK-UHFFFAOYSA-N n-(diaminomethylidene)-5-propan-2-yl-1-quinolin-6-ylpyrazole-4-carboxamide Chemical compound CC(C)C1=C(C(=O)NC(N)=N)C=NN1C1=CC=C(N=CC=C2)C2=C1 IJZQRLYNEVAONK-UHFFFAOYSA-N 0.000 claims description 2
125000003718 tetrahydrofuranyl group Chemical group 0.000 claims description 2
XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 claims 3
GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 claims 3
229940122106 Pyruvate dehydrogenase kinase inhibitor Drugs 0.000 claims 3
239000003146 anticoagulant agent Substances 0.000 claims 3
229960002896 clonidine Drugs 0.000 claims 3
229960002768 dipyridamole Drugs 0.000 claims 3
IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 claims 3
230000001882 diuretic effect Effects 0.000 claims 3
YHBCRXAIIVZWEW-UHFFFAOYSA-N 2-[3-(diaminomethylideneamino)phenyl]-3-sulfanylpropanoic acid Chemical compound NC(=N)NC1=CC=CC(C(CS)C(O)=O)=C1 YHBCRXAIIVZWEW-UHFFFAOYSA-N 0.000 claims 2
108700038202 AMP-Activated Protein Kinase Kinases Proteins 0.000 claims 2
229940110394 C5a inhibitor Drugs 0.000 claims 2
229940123169 Caspase inhibitor Drugs 0.000 claims 2
229940122783 Endothelin converting-enzyme inhibitor Drugs 0.000 claims 2
102000010180 Endothelin receptor Human genes 0.000 claims 2
108050001739 Endothelin receptor Proteins 0.000 claims 2
229940122355 Insulin sensitizer Drugs 0.000 claims 2
229940122874 Malonyl-CoA decarboxylase inhibitor Drugs 0.000 claims 2
239000002333 angiotensin II receptor antagonist Substances 0.000 claims 2
229940126317 angiotensin II receptor antagonist Drugs 0.000 claims 2
230000002424 anti-apoptotic effect Effects 0.000 claims 2
108010073240 complement C5a-inhibitors Proteins 0.000 claims 2
102000006834 complement receptors Human genes 0.000 claims 2
108010047295 complement receptors Proteins 0.000 claims 2
239000002857 endothelin converting enzyme inhibitor Substances 0.000 claims 2
229940035032 monophosphoryl lipid a Drugs 0.000 claims 2
239000004036 potassium channel stimulating agent Substances 0.000 claims 2
229940121649 protein inhibitor Drugs 0.000 claims 2
239000012268 protein inhibitor Substances 0.000 claims 2
JMXVATATTWHXNZ-UHFFFAOYSA-N 1-(6-chloroquinolin-5-yl)-5-cyclopropyl-n-(diaminomethylidene)pyrazole-4-carboxamide Chemical compound NC(=N)NC(=O)C=1C=NN(C=2C3=CC=CN=C3C=CC=2Cl)C=1C1CC1 JMXVATATTWHXNZ-UHFFFAOYSA-N 0.000 claims 1
125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 claims 1
125000003830 C1- C4 alkylcarbonylamino group Chemical group 0.000 claims 1
125000003282 alkyl amino group Chemical group 0.000 claims 1
229940125507 complex inhibitor Drugs 0.000 claims 1
125000005144 cycloalkylsulfonyl group Chemical group 0.000 claims 1
WZNARTSEKZYYQH-UHFFFAOYSA-N n-(diaminomethylidene)-5-ethyl-1-quinolin-6-ylpyrazole-4-carboxamide Chemical compound CCC1=C(C(=O)NC(N)=N)C=NN1C1=CC=C(N=CC=C2)C2=C1 WZNARTSEKZYYQH-UHFFFAOYSA-N 0.000 claims 1
YUZRJRZCWFSHBF-UHFFFAOYSA-N n-(diaminomethylidene)-5-propyl-1-quinolin-6-ylpyrazole-4-carboxamide Chemical compound CCCC1=C(C(=O)NC(N)=N)C=NN1C1=CC=C(N=CC=C2)C2=C1 YUZRJRZCWFSHBF-UHFFFAOYSA-N 0.000 claims 1
125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 1
125000001412 tetrahydropyranyl group Chemical group 0.000 claims 1
230000009467 reduction Effects 0.000 abstract description 17
239000000556 agonist Substances 0.000 abstract description 10
238000005481 NMR spectroscopy Methods 0.000 description 132
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 84
238000006243 chemical reaction Methods 0.000 description 55
102000007390 Glycogen Phosphorylase Human genes 0.000 description 50
108010046163 Glycogen Phosphorylase Proteins 0.000 description 50
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 46
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 45
230000000694 effects Effects 0.000 description 45
238000002844 melting Methods 0.000 description 45
230000008018 melting Effects 0.000 description 45
210000004027 cell Anatomy 0.000 description 39
230000000302 ischemic effect Effects 0.000 description 37
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 35
150000001412 amines Chemical class 0.000 description 33
239000000243 solution Substances 0.000 description 31
239000002585 base Substances 0.000 description 29
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 27
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 27
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 26
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 25
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 25
229910052799 carbon Inorganic materials 0.000 description 24
238000012360 testing method Methods 0.000 description 23
239000002904 solvent Substances 0.000 description 22
239000002253 acid Substances 0.000 description 21
238000003556 assay Methods 0.000 description 21
IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 20
239000003826 tablet Substances 0.000 description 20
239000000872 buffer Substances 0.000 description 19
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 19
239000004480 active ingredient Substances 0.000 description 18
239000003288 aldose reductase inhibitor Substances 0.000 description 18
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 18
YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 18
102000004190 Enzymes Human genes 0.000 description 17
108090000790 Enzymes Proteins 0.000 description 17
YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 17
229940088598 enzyme Drugs 0.000 description 17
208000010125 myocardial infarction Diseases 0.000 description 17
230000004224 protection Effects 0.000 description 17
239000000126 substance Substances 0.000 description 17
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 16
230000006378 damage Effects 0.000 description 16
230000002107 myocardial effect Effects 0.000 description 16
230000001146 hypoxic effect Effects 0.000 description 15
239000011541 reaction mixture Substances 0.000 description 15
238000006722 reduction reaction Methods 0.000 description 15
239000002775 capsule Substances 0.000 description 14
239000011780 sodium chloride Substances 0.000 description 14
229920002527 Glycogen Polymers 0.000 description 13
201000010099 disease Diseases 0.000 description 13
239000003814 drug Substances 0.000 description 13
229940096919 glycogen Drugs 0.000 description 13
239000000523 sample Substances 0.000 description 13
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
229940118148 Aldose reductase inhibitor Drugs 0.000 description 12
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 12
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 12
229930091371 Fructose Natural products 0.000 description 12
239000005715 Fructose Substances 0.000 description 12
RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 12
230000005961 cardioprotection Effects 0.000 description 12
210000000056 organ Anatomy 0.000 description 12
230000010410 reperfusion Effects 0.000 description 12
239000000600 sorbitol Substances 0.000 description 12
RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 12
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 11
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 11
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 11
229960000583 acetic acid Drugs 0.000 description 11
238000009472 formulation Methods 0.000 description 11
239000002609 medium Substances 0.000 description 11
230000008569 process Effects 0.000 description 11
102000005962 receptors Human genes 0.000 description 11
108020003175 receptors Proteins 0.000 description 11
230000002829 reductive effect Effects 0.000 description 11
239000007787 solid Substances 0.000 description 11
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 10
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 10
DHCLVCXQIBBOPH-UHFFFAOYSA-N Glycerol 2-phosphate Chemical compound OCC(CO)OP(O)(O)=O DHCLVCXQIBBOPH-UHFFFAOYSA-N 0.000 description 10
239000007995 HEPES buffer Substances 0.000 description 10
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 10
230000004913 activation Effects 0.000 description 10
150000001408 amides Chemical class 0.000 description 10
230000000747 cardiac effect Effects 0.000 description 10
210000004351 coronary vessel Anatomy 0.000 description 10
229940079593 drug Drugs 0.000 description 10
230000002255 enzymatic effect Effects 0.000 description 10
239000012442 inert solvent Substances 0.000 description 10
ROJNYKZWTOHRNU-UHFFFAOYSA-N 2-chloro-4,5-difluoro-n-[[2-methoxy-5-(methylcarbamoylamino)phenyl]carbamoyl]benzamide Chemical compound CNC(=O)NC1=CC=C(OC)C(NC(=O)NC(=O)C=2C(=CC(F)=C(F)C=2)Cl)=C1 ROJNYKZWTOHRNU-UHFFFAOYSA-N 0.000 description 9
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 9
241000588724 Escherichia coli Species 0.000 description 9
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 9
241000700159 Rattus Species 0.000 description 9
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 9
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
150000001540 azides Chemical class 0.000 description 9
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 9
206010012601 diabetes mellitus Diseases 0.000 description 9
239000000499 gel Substances 0.000 description 9
239000008103 glucose Substances 0.000 description 9
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 9
230000005764 inhibitory process Effects 0.000 description 9
150000003254 radicals Chemical class 0.000 description 9
FUQOTYRCMBZFOL-UHFFFAOYSA-N 5-chloro-1H-indole-2-carboxylic acid Chemical compound ClC1=CC=C2NC(C(=O)O)=CC2=C1 FUQOTYRCMBZFOL-UHFFFAOYSA-N 0.000 description 8
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 8
WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 8
230000015572 biosynthetic process Effects 0.000 description 8
238000004587 chromatography analysis Methods 0.000 description 8
238000010511 deprotection reaction Methods 0.000 description 8
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 8
238000003818 flash chromatography Methods 0.000 description 8
238000001597 immobilized metal affinity chromatography Methods 0.000 description 8
230000002530 ischemic preconditioning effect Effects 0.000 description 8
229910001629 magnesium chloride Inorganic materials 0.000 description 8
239000000047 product Substances 0.000 description 8
VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 7
208000006011 Stroke Diseases 0.000 description 7
125000004453 alkoxycarbonyl group Chemical group 0.000 description 7
238000005804 alkylation reaction Methods 0.000 description 7
HXXFSFRBOHSIMQ-VFUOTHLCSA-N alpha-D-glucose 1-phosphate Chemical compound OC[C@H]1O[C@H](OP(O)(O)=O)[C@H](O)[C@@H](O)[C@@H]1O HXXFSFRBOHSIMQ-VFUOTHLCSA-N 0.000 description 7
239000000908 ammonium hydroxide Substances 0.000 description 7
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 7
238000005119 centrifugation Methods 0.000 description 7
239000003153 chemical reaction reagent Substances 0.000 description 7
208000029078 coronary artery disease Diseases 0.000 description 7
239000007822 coupling agent Substances 0.000 description 7
230000004064 dysfunction Effects 0.000 description 7
229950010772 glucose-1-phosphate Drugs 0.000 description 7
230000001939 inductive effect Effects 0.000 description 7
238000001802 infusion Methods 0.000 description 7
239000004615 ingredient Substances 0.000 description 7
BAVYZALUXZFZLV-UHFFFAOYSA-N mono-methylamine Natural products NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 7
208000031225 myocardial ischemia Diseases 0.000 description 7
210000004165 myocardium Anatomy 0.000 description 7
239000008188 pellet Substances 0.000 description 7
238000002360 preparation method Methods 0.000 description 7
125000005495 pyridazyl group Chemical group 0.000 description 7
239000000741 silica gel Substances 0.000 description 7
229910002027 silica gel Inorganic materials 0.000 description 7
PKDBCJSWQUOKDO-UHFFFAOYSA-M 2,3,5-triphenyltetrazolium chloride Chemical compound [Cl-].C1=CC=CC=C1C(N=[N+]1C=2C=CC=CC=2)=NN1C1=CC=CC=C1 PKDBCJSWQUOKDO-UHFFFAOYSA-M 0.000 description 6
UDMBCSSLTHHNCD-UHFFFAOYSA-N Coenzym Q(11) Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1O UDMBCSSLTHHNCD-UHFFFAOYSA-N 0.000 description 6
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 6
206010061216 Infarction Diseases 0.000 description 6
241001465754 Metazoa Species 0.000 description 6
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 6
229950006790 adenosine phosphate Drugs 0.000 description 6
229940090865 aldose reductase inhibitors used in diabetes Drugs 0.000 description 6
230000029936 alkylation Effects 0.000 description 6
239000007864 aqueous solution Substances 0.000 description 6
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 6
150000002148 esters Chemical class 0.000 description 6
MNQZXJOMYWMBOU-UHFFFAOYSA-N glyceraldehyde Chemical compound OCC(O)C=O MNQZXJOMYWMBOU-UHFFFAOYSA-N 0.000 description 6
210000005003 heart tissue Anatomy 0.000 description 6
125000002883 imidazolyl group Chemical group 0.000 description 6
238000001727 in vivo Methods 0.000 description 6
238000011534 incubation Methods 0.000 description 6
230000007574 infarction Effects 0.000 description 6
230000002401 inhibitory effect Effects 0.000 description 6
239000000543 intermediate Substances 0.000 description 6
238000001990 intravenous administration Methods 0.000 description 6
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 6
CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 6
239000002953 phosphate buffered saline Substances 0.000 description 6
235000018102 proteins Nutrition 0.000 description 6
102000004169 proteins and genes Human genes 0.000 description 6
108090000623 proteins and genes Proteins 0.000 description 6
238000003786 synthesis reaction Methods 0.000 description 6
238000002054 transplantation Methods 0.000 description 6
230000002861 ventricular Effects 0.000 description 6
108050000203 Adenosine receptors Proteins 0.000 description 5
102000009346 Adenosine receptors Human genes 0.000 description 5
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 5
VOPWNXZWBYDODV-UHFFFAOYSA-N Chlorodifluoromethane Chemical compound FC(F)Cl VOPWNXZWBYDODV-UHFFFAOYSA-N 0.000 description 5
101000702479 Homo sapiens Sodium/hydrogen exchanger 1 Proteins 0.000 description 5
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 5
GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 5
241000283973 Oryctolagus cuniculus Species 0.000 description 5
108091000080 Phosphotransferase Proteins 0.000 description 5
229920002472 Starch Polymers 0.000 description 5
239000000010 aprotic solvent Substances 0.000 description 5
206010003119 arrhythmia Diseases 0.000 description 5
230000006793 arrhythmia Effects 0.000 description 5
125000004429 atom Chemical group 0.000 description 5
239000011324 bead Substances 0.000 description 5
230000027455 binding Effects 0.000 description 5
238000009739 binding Methods 0.000 description 5
239000001110 calcium chloride Substances 0.000 description 5
229910001628 calcium chloride Inorganic materials 0.000 description 5
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 5
238000007675 cardiac surgery Methods 0.000 description 5
230000004087 circulation Effects 0.000 description 5
239000002299 complementary DNA Substances 0.000 description 5
238000006482 condensation reaction Methods 0.000 description 5
230000008878 coupling Effects 0.000 description 5
238000010168 coupling process Methods 0.000 description 5
238000005859 coupling reaction Methods 0.000 description 5
208000035475 disorder Diseases 0.000 description 5
239000000284 extract Substances 0.000 description 5
125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 5
125000005843 halogen group Chemical group 0.000 description 5
125000000623 heterocyclic group Chemical group 0.000 description 5
238000002347 injection Methods 0.000 description 5
239000007924 injection Substances 0.000 description 5
229910052816 inorganic phosphate Inorganic materials 0.000 description 5
229910052740 iodine Inorganic materials 0.000 description 5
GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 5
108010052968 leupeptin Proteins 0.000 description 5
230000007774 longterm Effects 0.000 description 5
229920002521 macromolecule Polymers 0.000 description 5
239000000463 material Substances 0.000 description 5
238000012544 monitoring process Methods 0.000 description 5
230000000144 pharmacologic effect Effects 0.000 description 5
102000020233 phosphotransferase Human genes 0.000 description 5
239000002798 polar solvent Substances 0.000 description 5
238000000746 purification Methods 0.000 description 5
229910052708 sodium Inorganic materials 0.000 description 5
238000012289 standard assay Methods 0.000 description 5
239000008107 starch Substances 0.000 description 5
235000019698 starch Nutrition 0.000 description 5
239000000725 suspension Substances 0.000 description 5
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 5
NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 4
SMNDYUVBFMFKNZ-UHFFFAOYSA-N 2-furoic acid Chemical compound OC(=O)C1=CC=CO1 SMNDYUVBFMFKNZ-UHFFFAOYSA-N 0.000 description 4
BCSVCWVQNOXFGL-UHFFFAOYSA-N 3,4-dihydro-4-oxo-3-((5-trifluoromethyl-2-benzothiazolyl)methyl)-1-phthalazine acetic acid Chemical compound O=C1C2=CC=CC=C2C(CC(=O)O)=NN1CC1=NC2=CC(C(F)(F)F)=CC=C2S1 BCSVCWVQNOXFGL-UHFFFAOYSA-N 0.000 description 4
101710169336 5'-deoxyadenosine deaminase Proteins 0.000 description 4
FLDSMVTWEZKONL-AWEZNQCLSA-N 5,5-dimethyl-N-[(3S)-5-methyl-4-oxo-2,3-dihydro-1,5-benzoxazepin-3-yl]-1,4,7,8-tetrahydrooxepino[4,5-c]pyrazole-3-carboxamide Chemical compound CC1(CC2=C(NN=C2C(=O)N[C@@H]2C(N(C3=C(OC2)C=CC=C3)C)=O)CCO1)C FLDSMVTWEZKONL-AWEZNQCLSA-N 0.000 description 4
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 4
102000055025 Adenosine deaminases Human genes 0.000 description 4
102000016912 Aldehyde Reductase Human genes 0.000 description 4
108010053754 Aldehyde reductase Proteins 0.000 description 4
206010002388 Angina unstable Diseases 0.000 description 4
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
206010019280 Heart failures Diseases 0.000 description 4
241000282412 Homo Species 0.000 description 4
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
102000014750 Phosphorylase Kinase Human genes 0.000 description 4
108010064071 Phosphorylase Kinase Proteins 0.000 description 4
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 4
229920002684 Sepharose Polymers 0.000 description 4
208000007814 Unstable Angina Diseases 0.000 description 4
XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 4
WFDIJRYMOXRFFG-UHFFFAOYSA-N acetic acid anhydride Natural products CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 4
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 4
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 4
230000002378 acidificating effect Effects 0.000 description 4
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
150000003939 benzylamines Chemical class 0.000 description 4
230000000903 blocking effect Effects 0.000 description 4
230000036760 body temperature Effects 0.000 description 4
RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 4
208000026106 cerebrovascular disease Diseases 0.000 description 4
238000000170 chemical ionisation mass spectrum Methods 0.000 description 4
238000010367 cloning Methods 0.000 description 4
238000007887 coronary angioplasty Methods 0.000 description 4
DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 4
230000005284 excitation Effects 0.000 description 4
230000014509 gene expression Effects 0.000 description 4
238000005462 in vivo assay Methods 0.000 description 4
201000004332 intermediate coronary syndrome Diseases 0.000 description 4
239000011777 magnesium Substances 0.000 description 4
229910052943 magnesium sulfate Inorganic materials 0.000 description 4
235000019341 magnesium sulphate Nutrition 0.000 description 4
238000004519 manufacturing process Methods 0.000 description 4
230000003680 myocardial damage Effects 0.000 description 4
239000002245 particle Substances 0.000 description 4
108010091212 pepstatin Proteins 0.000 description 4
FAXGPCHRFPCXOO-LXTPJMTPSA-N pepstatin A Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-LXTPJMTPSA-N 0.000 description 4
VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 4
230000010412 perfusion Effects 0.000 description 4
239000011591 potassium Substances 0.000 description 4
229910052700 potassium Inorganic materials 0.000 description 4
239000000843 powder Substances 0.000 description 4
230000000069 prophylactic effect Effects 0.000 description 4
LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 4
238000010992 reflux Methods 0.000 description 4
238000011160 research Methods 0.000 description 4
230000002441 reversible effect Effects 0.000 description 4
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
238000013222 sprague-dawley male rat Methods 0.000 description 4
239000007858 starting material Substances 0.000 description 4
239000000829 suppository Substances 0.000 description 4
IMCGHZIGRANKHV-AJNGGQMLSA-N tert-butyl (3s,5s)-2-oxo-5-[(2s,4s)-5-oxo-4-propan-2-yloxolan-2-yl]-3-propan-2-ylpyrrolidine-1-carboxylate Chemical compound O1C(=O)[C@H](C(C)C)C[C@H]1[C@H]1N(C(=O)OC(C)(C)C)C(=O)[C@H](C(C)C)C1 IMCGHZIGRANKHV-AJNGGQMLSA-N 0.000 description 4
238000007631 vascular surgery Methods 0.000 description 4
JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 3
125000006699 (C1-C3) hydroxyalkyl group Chemical group 0.000 description 3
125000003363 1,3,5-triazinyl group Chemical group N1=C(N=CN=C1)* 0.000 description 3
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
JMTMSDXUXJISAY-UHFFFAOYSA-N 2H-benzotriazol-4-ol Chemical compound OC1=CC=CC2=C1N=NN2 JMTMSDXUXJISAY-UHFFFAOYSA-N 0.000 description 3
KTEPYJGLVNSCFD-UHFFFAOYSA-N 4-hydroxyoxolane-2-carboxylic acid Chemical compound OC1COC(C(O)=O)C1 KTEPYJGLVNSCFD-UHFFFAOYSA-N 0.000 description 3
GZILZCCGDNKAAV-UHFFFAOYSA-N 5-chloro-1h-indole-2-carboxamide Chemical compound ClC1=CC=C2NC(C(=O)N)=CC2=C1 GZILZCCGDNKAAV-UHFFFAOYSA-N 0.000 description 3
ZKBQDFAWXLTYKS-UHFFFAOYSA-N 6-Chloro-1H-purine Chemical compound ClC1=NC=NC2=C1NC=N2 ZKBQDFAWXLTYKS-UHFFFAOYSA-N 0.000 description 3
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
208000002109 Argyria Diseases 0.000 description 3
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
108091003079 Bovine Serum Albumin Proteins 0.000 description 3
208000024172 Cardiovascular disease Diseases 0.000 description 3
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 3
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
102000003855 L-lactate dehydrogenase Human genes 0.000 description 3
108700023483 L-lactate dehydrogenases Proteins 0.000 description 3
WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
229920000168 Microcrystalline cellulose Polymers 0.000 description 3
PLXBWHJQWKZRKG-UHFFFAOYSA-N Resazurin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3[N+]([O-])=C21 PLXBWHJQWKZRKG-UHFFFAOYSA-N 0.000 description 3
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
238000002835 absorbance Methods 0.000 description 3
239000002593 adenosine A3 receptor agonist Substances 0.000 description 3
125000004183 alkoxy alkyl group Chemical group 0.000 description 3
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 3
229960000723 ampicillin Drugs 0.000 description 3
210000001367 artery Anatomy 0.000 description 3
125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 3
150000001721 carbon Chemical group 0.000 description 3
239000003054 catalyst Substances 0.000 description 3
230000003197 catalytic effect Effects 0.000 description 3
150000001768 cations Chemical class 0.000 description 3
239000013592 cell lysate Substances 0.000 description 3
206010008118 cerebral infarction Diseases 0.000 description 3
210000000038 chest Anatomy 0.000 description 3
238000011210 chromatographic step Methods 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
238000003776 cleavage reaction Methods 0.000 description 3
VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 3
239000006167 equilibration buffer Substances 0.000 description 3
238000001914 filtration Methods 0.000 description 3
239000000796 flavoring agent Substances 0.000 description 3
235000019634 flavors Nutrition 0.000 description 3
229910052731 fluorine Inorganic materials 0.000 description 3
239000011888 foil Substances 0.000 description 3
238000005858 glycosidation reaction Methods 0.000 description 3
BCQZXOMGPXTTIC-UHFFFAOYSA-N halothane Chemical compound FC(F)(F)C(Cl)Br BCQZXOMGPXTTIC-UHFFFAOYSA-N 0.000 description 3
229960003132 halothane Drugs 0.000 description 3
NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 3
238000000099 in vitro assay Methods 0.000 description 3
230000003834 intracellular effect Effects 0.000 description 3
239000007927 intramuscular injection Substances 0.000 description 3
238000010253 intravenous injection Methods 0.000 description 3
150000002500 ions Chemical class 0.000 description 3
208000037906 ischaemic injury Diseases 0.000 description 3
238000001155 isoelectric focusing Methods 0.000 description 3
229940039009 isoproterenol Drugs 0.000 description 3
239000007788 liquid Substances 0.000 description 3
235000019359 magnesium stearate Nutrition 0.000 description 3
230000001404 mediated effect Effects 0.000 description 3
229910052987 metal hydride Inorganic materials 0.000 description 3
150000004681 metal hydrides Chemical class 0.000 description 3
235000019813 microcrystalline cellulose Nutrition 0.000 description 3
238000004806 packaging method and process Methods 0.000 description 3
WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 3
125000003884 phenylalkyl group Chemical group 0.000 description 3
RFIOZSIHFNEKFF-UHFFFAOYSA-N piperazine-1-carboxylic acid Chemical compound OC(=O)N1CCNCC1 RFIOZSIHFNEKFF-UHFFFAOYSA-N 0.000 description 3
125000005936 piperidyl group Chemical group 0.000 description 3
239000000902 placebo Substances 0.000 description 3
229940068196 placebo Drugs 0.000 description 3
239000013612 plasmid Substances 0.000 description 3
239000002985 plastic film Substances 0.000 description 3
229920006255 plastic film Polymers 0.000 description 3
239000003880 polar aprotic solvent Substances 0.000 description 3
239000001267 polyvinylpyrrolidone Substances 0.000 description 3
229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
230000001292 preischemic effect Effects 0.000 description 3
230000002265 prevention Effects 0.000 description 3
125000006239 protecting group Chemical group 0.000 description 3
125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 3
125000003072 pyrazolidinyl group Chemical group 0.000 description 3
125000002755 pyrazolinyl group Chemical group 0.000 description 3
238000011084 recovery Methods 0.000 description 3
230000007017 scission Effects 0.000 description 3
229910052709 silver Inorganic materials 0.000 description 3
239000004332 silver Substances 0.000 description 3
239000000454 talc Substances 0.000 description 3
229910052623 talc Inorganic materials 0.000 description 3
235000012222 talc Nutrition 0.000 description 3
LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 3
229910052727 yttrium Inorganic materials 0.000 description 3
REGZQZHKIFOMRK-LSCFUAHRSA-N (2r,3r,4s,5r)-2-[6-[(4-amino-3-iodophenyl)methylamino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C1=C(I)C(N)=CC=C1CNC1=NC=NC2=C1N=CN2[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 REGZQZHKIFOMRK-LSCFUAHRSA-N 0.000 description 2
NVOQTJOPEVSGOF-QYUDBREXSA-N (2s,3s,4r,5r)-3-amino-5-[6-[[5-chloro-2-(furan-3-ylmethoxy)phenyl]methylamino]purin-9-yl]-4-hydroxy-n-methyloxolane-2-carboxamide Chemical compound O[C@@H]1[C@H](N)[C@@H](C(=O)NC)O[C@H]1N1C2=NC=NC(NCC=3C(=CC=C(Cl)C=3)OCC3=COC=C3)=C2N=C1 NVOQTJOPEVSGOF-QYUDBREXSA-N 0.000 description 2
PGLASKORVDVZEZ-UHFFFAOYSA-N (2z)-1-cycloundecyl-2-diazocycloundecane Chemical compound [N-]=[N+]=C1CCCCCCCCCC1C1CCCCCCCCCC1 PGLASKORVDVZEZ-UHFFFAOYSA-N 0.000 description 2
125000004844 (C1-C6) alkoxyimino group Chemical group 0.000 description 2
SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 2
IRQHMLZBZSIPCM-UHFFFAOYSA-N 1-(2-chlorophenyl)-n-(diaminomethylidene)-5-methylpyrazole-4-carboxamide Chemical compound CC1=C(C(=O)NC(N)=N)C=NN1C1=CC=CC=C1Cl IRQHMLZBZSIPCM-UHFFFAOYSA-N 0.000 description 2
XLMUCHBVEFPSRM-UHFFFAOYSA-N 1-(8-bromoquinolin-5-yl)-5-cyclopropyl-n-(diaminomethylidene)pyrazole-4-carboxamide Chemical compound NC(=N)NC(=O)C=1C=NN(C=2C3=CC=CN=C3C(Br)=CC=2)C=1C1CC1 XLMUCHBVEFPSRM-UHFFFAOYSA-N 0.000 description 2
LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 2
VMJNTFXCTXAXTC-UHFFFAOYSA-N 2,2-difluoro-1,3-benzodioxole-5-carbonitrile Chemical group C1=C(C#N)C=C2OC(F)(F)OC2=C1 VMJNTFXCTXAXTC-UHFFFAOYSA-N 0.000 description 2
HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
LKBFFDOJUKLQNY-UHFFFAOYSA-N 2-[3-[(4-bromo-2-fluorophenyl)methyl]-4-oxo-1-phthalazinyl]acetic acid Chemical compound O=C1C2=CC=CC=C2C(CC(=O)O)=NN1CC1=CC=C(Br)C=C1F LKBFFDOJUKLQNY-UHFFFAOYSA-N 0.000 description 2
BUYWFAJWTSIACV-UHFFFAOYSA-N 2-[3-oxo-4-[(4,5,7-trifluoro-1,3-benzothiazol-2-yl)methyl]-1,4-benzothiazin-2-yl]acetic acid Chemical compound FC1=CC(F)=C2SC(CN3C4=CC=CC=C4SC(C3=O)CC(=O)O)=NC2=C1F BUYWFAJWTSIACV-UHFFFAOYSA-N 0.000 description 2
FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 2
VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
VFTOHJFKIJLYKN-UHFFFAOYSA-N 7-nitro-9h-fluoren-2-ol Chemical group [O-][N+](=O)C1=CC=C2C3=CC=C(O)C=C3CC2=C1 VFTOHJFKIJLYKN-UHFFFAOYSA-N 0.000 description 2
208000004476 Acute Coronary Syndrome Diseases 0.000 description 2
208000009304 Acute Kidney Injury Diseases 0.000 description 2
GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical class NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 2
102100036475 Alanine aminotransferase 1 Human genes 0.000 description 2
108010082126 Alanine transaminase Proteins 0.000 description 2
NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
206010002091 Anaesthesia Diseases 0.000 description 2
206010002383 Angina Pectoris Diseases 0.000 description 2
102000008873 Angiotensin II receptor Human genes 0.000 description 2
108050000824 Angiotensin II receptor Proteins 0.000 description 2
206010003210 Arteriosclerosis Diseases 0.000 description 2
108010003415 Aspartate Aminotransferases Proteins 0.000 description 2
102000004625 Aspartate Aminotransferases Human genes 0.000 description 2
239000005711 Benzoic acid Substances 0.000 description 2
206010048962 Brain oedema Diseases 0.000 description 2
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
IUBQUWJRKSLQTD-UHFFFAOYSA-N CNN1C2=NC=NC(NCC(C=C(C=C3)Cl)=C3OCC(N3CCN(CC4=CC=CC=C4)CC3)=O)=C2N=C1.OC(C1)COC1C(O)=O Chemical compound CNN1C2=NC=NC(NCC(C=C(C=C3)Cl)=C3OCC(N3CCN(CC4=CC=CC=C4)CC3)=O)=C2N=C1.OC(C1)COC1C(O)=O IUBQUWJRKSLQTD-UHFFFAOYSA-N 0.000 description 2
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
206010007572 Cardiac hypertrophy Diseases 0.000 description 2
208000006029 Cardiomegaly Diseases 0.000 description 2
101710088194 Dehydrogenase Proteins 0.000 description 2
108020005199 Dehydrogenases Proteins 0.000 description 2
102000048186 Endothelin-converting enzyme 1 Human genes 0.000 description 2
108030001679 Endothelin-converting enzyme 1 Proteins 0.000 description 2
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
206010020880 Hypertrophy Diseases 0.000 description 2
LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 2
108010009384 L-Iditol 2-Dehydrogenase Proteins 0.000 description 2
239000002841 Lewis acid Substances 0.000 description 2
206010067125 Liver injury Diseases 0.000 description 2
206010028851 Necrosis Diseases 0.000 description 2
GQPLMRYTRLFLPF-UHFFFAOYSA-N Nitrous Oxide Chemical compound [O-][N+]#N GQPLMRYTRLFLPF-UHFFFAOYSA-N 0.000 description 2
QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 2
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
208000033626 Renal failure acute Diseases 0.000 description 2
101000650578 Salmonella phage P22 Regulatory protein C3 Proteins 0.000 description 2
206010040070 Septic Shock Diseases 0.000 description 2
229910004298 SiO 2 Inorganic materials 0.000 description 2
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 2
102100026974 Sorbitol dehydrogenase Human genes 0.000 description 2
229940123659 Sorbitol dehydrogenase inhibitor Drugs 0.000 description 2
101001040920 Triticum aestivum Alpha-amylase inhibitor 0.28 Proteins 0.000 description 2
RGTGNSLGFMHBDM-UHFFFAOYSA-J [Zn++].[Cd++].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O Chemical compound [Zn++].[Cd++].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O RGTGNSLGFMHBDM-UHFFFAOYSA-J 0.000 description 2
239000002250 absorbent Substances 0.000 description 2
230000002745 absorbent Effects 0.000 description 2
201000011040 acute kidney failure Diseases 0.000 description 2
208000012998 acute renal failure Diseases 0.000 description 2
230000010933 acylation Effects 0.000 description 2
238000005917 acylation reaction Methods 0.000 description 2
ORILYTVJVMAKLC-UHFFFAOYSA-N adamantane Chemical compound C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 description 2
150000003835 adenosine derivatives Chemical class 0.000 description 2
150000003838 adenosines Chemical class 0.000 description 2
239000000443 aerosol Substances 0.000 description 2
230000001476 alcoholic effect Effects 0.000 description 2
125000000676 alkoxyimino group Chemical group 0.000 description 2
229910052782 aluminium Inorganic materials 0.000 description 2
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
125000004103 aminoalkyl group Chemical group 0.000 description 2
230000037005 anaesthesia Effects 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
238000005571 anion exchange chromatography Methods 0.000 description 2
150000001450 anions Chemical class 0.000 description 2
230000003288 anthiarrhythmic effect Effects 0.000 description 2
239000003416 antiarrhythmic agent Substances 0.000 description 2
230000006907 apoptotic process Effects 0.000 description 2
239000012736 aqueous medium Substances 0.000 description 2
208000011775 arteriosclerosis disease Diseases 0.000 description 2
239000012131 assay buffer Substances 0.000 description 2
239000012298 atmosphere Substances 0.000 description 2
230000008901 benefit Effects 0.000 description 2
JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical class C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 2
235000010233 benzoic acid Nutrition 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000008280 blood Substances 0.000 description 2
230000017531 blood circulation Effects 0.000 description 2
208000006752 brain edema Diseases 0.000 description 2
208000029028 brain injury Diseases 0.000 description 2
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
229910052794 bromium Inorganic materials 0.000 description 2
VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 2
229960001948 caffeine Drugs 0.000 description 2
239000001506 calcium phosphate Substances 0.000 description 2
229910000389 calcium phosphate Inorganic materials 0.000 description 2
235000011010 calcium phosphates Nutrition 0.000 description 2
229940041514 candida albicans extract Drugs 0.000 description 2
239000001569 carbon dioxide Substances 0.000 description 2
229910002092 carbon dioxide Inorganic materials 0.000 description 2
239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
125000005708 carbonyloxy group Chemical group [*:2]OC([*:1])=O 0.000 description 2
239000001768 carboxy methyl cellulose Substances 0.000 description 2
125000004181 carboxyalkyl group Chemical group 0.000 description 2
229920003123 carboxymethyl cellulose sodium Polymers 0.000 description 2
229940063834 carboxymethylcellulose sodium Drugs 0.000 description 2
230000015556 catabolic process Effects 0.000 description 2
238000009903 catalytic hydrogenation reaction Methods 0.000 description 2
230000002490 cerebral effect Effects 0.000 description 2
239000003638 chemical reducing agent Substances 0.000 description 2
239000003086 colorant Substances 0.000 description 2
238000002648 combination therapy Methods 0.000 description 2
238000007796 conventional method Methods 0.000 description 2
239000006184 cosolvent Substances 0.000 description 2
238000006731 degradation reaction Methods 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 2
XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 2
230000002526 effect on cardiovascular system Effects 0.000 description 2
125000004494 ethyl ester group Chemical group 0.000 description 2
238000001704 evaporation Methods 0.000 description 2
230000008020 evaporation Effects 0.000 description 2
230000001747 exhibiting effect Effects 0.000 description 2
239000012894 fetal calf serum Substances 0.000 description 2
239000011737 fluorine Substances 0.000 description 2
125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 2
239000006260 foam Substances 0.000 description 2
FATAVLOOLIRUNA-UHFFFAOYSA-N formylmethyl Chemical group [CH2]C=O FATAVLOOLIRUNA-UHFFFAOYSA-N 0.000 description 2
125000000524 functional group Chemical group 0.000 description 2
229920000159 gelatin Polymers 0.000 description 2
239000007903 gelatin capsule Substances 0.000 description 2
235000019322 gelatine Nutrition 0.000 description 2
239000011521 glass Substances 0.000 description 2
125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 2
239000008187 granular material Substances 0.000 description 2
239000001963 growth medium Substances 0.000 description 2
238000010438 heat treatment Methods 0.000 description 2
FFUAGWLWBBFQJT-UHFFFAOYSA-N hexamethyldisilazane Chemical compound C[Si](C)(C)N[Si](C)(C)C FFUAGWLWBBFQJT-UHFFFAOYSA-N 0.000 description 2
150000004677 hydrates Chemical class 0.000 description 2
125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
238000005984 hydrogenation reaction Methods 0.000 description 2
125000002768 hydroxyalkyl group Chemical group 0.000 description 2
206010020718 hyperplasia Diseases 0.000 description 2
150000003949 imides Chemical class 0.000 description 2
125000001841 imino group Chemical group [H]N=* 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
230000012105 intracellular pH reduction Effects 0.000 description 2
238000007918 intramuscular administration Methods 0.000 description 2
238000010255 intramuscular injection Methods 0.000 description 2
208000017169 kidney disease Diseases 0.000 description 2
238000000021 kinase assay Methods 0.000 description 2
150000007517 lewis acids Chemical class 0.000 description 2
238000012417 linear regression Methods 0.000 description 2
125000005647 linker group Chemical group 0.000 description 2
210000005228 liver tissue Anatomy 0.000 description 2
239000006166 lysate Substances 0.000 description 2
238000005259 measurement Methods 0.000 description 2
239000012528 membrane Substances 0.000 description 2
125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 2
239000008108 microcrystalline cellulose Substances 0.000 description 2
229940016286 microcrystalline cellulose Drugs 0.000 description 2
238000002156 mixing Methods 0.000 description 2
208000002089 myocardial stunning Diseases 0.000 description 2
229950006238 nadide Drugs 0.000 description 2
230000017074 necrotic cell death Effects 0.000 description 2
210000005036 nerve Anatomy 0.000 description 2
231100000252 nontoxic Toxicity 0.000 description 2
230000003000 nontoxic effect Effects 0.000 description 2
239000003182 parenteral nutrition solution Substances 0.000 description 2
229960001412 pentobarbital Drugs 0.000 description 2
229960002275 pentobarbital sodium Drugs 0.000 description 2
239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
HXITXNWTGFUOAU-UHFFFAOYSA-N phenylboronic acid Chemical compound OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 description 2
UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 2
239000006187 pill Substances 0.000 description 2
125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 2
239000003586 protic polar solvent Substances 0.000 description 2
235000008160 pyridoxine Nutrition 0.000 description 2
239000011677 pyridoxine Substances 0.000 description 2
238000000611 regression analysis Methods 0.000 description 2
239000011347 resin Substances 0.000 description 2
229920005989 resin Polymers 0.000 description 2
HSSLDCABUXLXKM-UHFFFAOYSA-N resorufin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3N=C21 HSSLDCABUXLXKM-UHFFFAOYSA-N 0.000 description 2
208000037803 restenosis Diseases 0.000 description 2
WOCIAKWEIIZHES-UHFFFAOYSA-N ruthenium(iv) oxide Chemical compound O=[Ru]=O WOCIAKWEIIZHES-UHFFFAOYSA-N 0.000 description 2
229930195734 saturated hydrocarbon Natural products 0.000 description 2
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
239000012312 sodium hydride Substances 0.000 description 2
229910000104 sodium hydride Inorganic materials 0.000 description 2
JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 2
239000012453 solvate Substances 0.000 description 2
238000010186 staining Methods 0.000 description 2
229910001220 stainless steel Inorganic materials 0.000 description 2
239000010935 stainless steel Substances 0.000 description 2
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 2
229960001052 streptozocin Drugs 0.000 description 2
238000005556 structure-activity relationship Methods 0.000 description 2
239000000758 substrate Substances 0.000 description 2
239000006228 supernatant Substances 0.000 description 2
239000006188 syrup Substances 0.000 description 2
235000020357 syrup Nutrition 0.000 description 2
RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Substances C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
238000009210 therapy by ultrasound Methods 0.000 description 2
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
WJKHJLXJJJATHN-UHFFFAOYSA-N triflic anhydride Chemical compound FC(F)(F)S(=O)(=O)OS(=O)(=O)C(F)(F)F WJKHJLXJJJATHN-UHFFFAOYSA-N 0.000 description 2
LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
239000012137 tryptone Substances 0.000 description 2
229940011671 vitamin b6 Drugs 0.000 description 2
238000005406 washing Methods 0.000 description 2
239000012138 yeast extract Substances 0.000 description 2
SXONDGSPUVNZLO-UHFFFAOYSA-N zenarestat Chemical compound O=C1N(CC(=O)O)C2=CC(Cl)=CC=C2C(=O)N1CC1=CC=C(Br)C=C1F SXONDGSPUVNZLO-UHFFFAOYSA-N 0.000 description 2
JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 2
229950005346 zopolrestat Drugs 0.000 description 2
REGZQZHKIFOMRK-RWXWJUJFSA-N (2R,3R,4S,5R)-2-[6-[(4-amino-3-(125I)iodanylphenyl)methylamino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound NC1=C(C=C(CNC=2C=3N=CN([C@H]4[C@H](O)[C@H](O)[C@@H](CO)O4)C=3N=CN=2)C=C1)[125I] REGZQZHKIFOMRK-RWXWJUJFSA-N 0.000 description 1
PRYCPQVARRDRFD-LBPRGKRZSA-N (2S)-2-amino-1-(3-hydroxyiminopyrrolidin-1-yl)-3-phenylpropan-1-one Chemical compound C1CN(CC1=NO)C(=O)[C@H](CC2=CC=CC=C2)N PRYCPQVARRDRFD-LBPRGKRZSA-N 0.000 description 1
SZIHJKIVFFMSDJ-XIXAVDCQSA-N (2S,3S,4R,5R)-3-amino-5-[6-[[5-chloro-2-[2-oxo-2-(4-propan-2-ylpiperazin-1-yl)ethoxy]phenyl]methylamino]purin-9-yl]-4-hydroxyoxolane-2-carboxylic acid Chemical compound N[C@@H]1[C@H](O[C@H]([C@@H]1O)N1C2=NC=NC(=C2N=C1)NCC1=C(C=CC(=C1)Cl)OCC(=O)N1CCN(CC1)C(C)C)C(=O)O SZIHJKIVFFMSDJ-XIXAVDCQSA-N 0.000 description 1
NXWGWUVGUSFQJC-GFCCVEGCSA-N (2r)-1-[(2-methyl-1h-indol-4-yl)oxy]-3-(propan-2-ylamino)propan-2-ol Chemical compound CC(C)NC[C@@H](O)COC1=CC=CC2=C1C=C(C)N2 NXWGWUVGUSFQJC-GFCCVEGCSA-N 0.000 description 1
XHRJGHCQQPETRH-KQYNXXCUSA-N (2r,3r,4s,5r)-2-(6-chloropurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(Cl)=C2N=C1 XHRJGHCQQPETRH-KQYNXXCUSA-N 0.000 description 1
NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 1
QPOFGPBNVJBCMF-BINBFKAUSA-N (2s,3s,4r,5r)-3-amino-4-hydroxy-5-[6-[(5-iodo-2-phenylmethoxyphenyl)methylamino]purin-9-yl]-n-methyloxolane-2-carboxamide Chemical compound O[C@@H]1[C@H](N)[C@@H](C(=O)NC)O[C@H]1N1C2=NC=NC(NCC=3C(=CC=C(I)C=3)OCC=3C=CC=CC=3)=C2N=C1 QPOFGPBNVJBCMF-BINBFKAUSA-N 0.000 description 1
RBFHNCDPGZBQQP-GGISIDAXSA-N (2s,3s,4r,5r)-3-amino-4-hydroxy-n-methyl-5-[6-[(5-methyl-2-phenylmethoxyphenyl)methylamino]purin-9-yl]oxolane-2-carboxamide Chemical compound O[C@@H]1[C@H](N)[C@@H](C(=O)NC)O[C@H]1N1C2=NC=NC(NCC=3C(=CC=C(C)C=3)OCC=3C=CC=CC=3)=C2N=C1 RBFHNCDPGZBQQP-GGISIDAXSA-N 0.000 description 1
QBKBRKWKCDHRBB-BINBFKAUSA-N (2s,3s,4r,5r)-3-amino-4-hydroxy-n-methyl-5-[6-[[2-phenylmethoxy-5-(trifluoromethyl)phenyl]methylamino]purin-9-yl]oxolane-2-carboxamide Chemical compound O[C@@H]1[C@H](N)[C@@H](C(=O)NC)O[C@H]1N1C2=NC=NC(NCC=3C(=CC=C(C=3)C(F)(F)F)OCC=3C=CC=CC=3)=C2N=C1 QBKBRKWKCDHRBB-BINBFKAUSA-N 0.000 description 1
MIBUXYSRAKWLCC-QLBZUPSYSA-N (2s,3s,4r,5r)-3-amino-5-[2-chloro-6-[(5-chloro-2-phenylmethoxyphenyl)methylamino]purin-9-yl]-4-hydroxy-n-methyloxolane-2-carboxamide Chemical compound O[C@@H]1[C@H](N)[C@@H](C(=O)NC)O[C@H]1N1C2=NC(Cl)=NC(NCC=3C(=CC=C(Cl)C=3)OCC=3C=CC=CC=3)=C2N=C1 MIBUXYSRAKWLCC-QLBZUPSYSA-N 0.000 description 1
MXDVKEIPWULGPG-BINBFKAUSA-N (2s,3s,4r,5r)-3-amino-5-[6-[(2-benzylsulfanyl-5-chlorophenyl)methylamino]purin-9-yl]-4-hydroxy-n-methyloxolane-2-carboxamide Chemical compound O[C@@H]1[C@H](N)[C@@H](C(=O)NC)O[C@H]1N1C2=NC=NC(NCC=3C(=CC=C(Cl)C=3)SCC=3C=CC=CC=3)=C2N=C1 MXDVKEIPWULGPG-BINBFKAUSA-N 0.000 description 1
OHDLXXYYMRWHDG-BINBFKAUSA-N (2s,3s,4r,5r)-3-amino-5-[6-[(5-bromo-2-phenylmethoxyphenyl)methylamino]purin-9-yl]-4-hydroxy-n-methyloxolane-2-carboxamide Chemical compound O[C@@H]1[C@H](N)[C@@H](C(=O)NC)O[C@H]1N1C2=NC=NC(NCC=3C(=CC=C(Br)C=3)OCC=3C=CC=CC=3)=C2N=C1 OHDLXXYYMRWHDG-BINBFKAUSA-N 0.000 description 1
CHWZXNHFXXEIRA-BINBFKAUSA-N (2s,3s,4r,5r)-3-amino-5-[6-[(5-chloro-2-phenylmethoxyphenyl)methylamino]purin-9-yl]-4-hydroxy-n-methyloxolane-2-carboxamide Chemical compound O[C@@H]1[C@H](N)[C@@H](C(=O)NC)O[C@H]1N1C2=NC=NC(NCC=3C(=CC=C(Cl)C=3)OCC=3C=CC=CC=3)=C2N=C1 CHWZXNHFXXEIRA-BINBFKAUSA-N 0.000 description 1
RSRYKWOKIWAOEH-GGISIDAXSA-N (2s,3s,4r,5r)-3-amino-5-[6-[(5-cyano-2-phenylmethoxyphenyl)methylamino]purin-9-yl]-4-hydroxy-n-methyloxolane-2-carboxamide Chemical compound O[C@@H]1[C@H](N)[C@@H](C(=O)NC)O[C@H]1N1C2=NC=NC(NCC=3C(=CC=C(C=3)C#N)OCC=3C=CC=CC=3)=C2N=C1 RSRYKWOKIWAOEH-GGISIDAXSA-N 0.000 description 1
JTTQNZDOCRGPFS-ONLLFZDPSA-N (2s,3s,4r,5r)-3-amino-5-[6-[(5-ethenyl-2-phenylmethoxyphenyl)methylamino]purin-9-yl]-4-hydroxy-n-methyloxolane-2-carboxamide Chemical compound O[C@@H]1[C@H](N)[C@@H](C(=O)NC)O[C@H]1N1C2=NC=NC(NCC=3C(=CC=C(C=C)C=3)OCC=3C=CC=CC=3)=C2N=C1 JTTQNZDOCRGPFS-ONLLFZDPSA-N 0.000 description 1
MPMDWHDDYYIXQU-ONLLFZDPSA-N (2s,3s,4r,5r)-3-amino-5-[6-[(5-ethynyl-2-phenylmethoxyphenyl)methylamino]purin-9-yl]-4-hydroxy-n-methyloxolane-2-carboxamide Chemical compound O[C@@H]1[C@H](N)[C@@H](C(=O)NC)O[C@H]1N1C2=NC=NC(NCC=3C(=CC=C(C=3)C#C)OCC=3C=CC=CC=3)=C2N=C1 MPMDWHDDYYIXQU-ONLLFZDPSA-N 0.000 description 1
JAKKCOVQWXMHGR-BINBFKAUSA-N (2s,3s,4r,5r)-3-amino-5-[6-[(5-fluoro-2-phenylmethoxyphenyl)methylamino]purin-9-yl]-4-hydroxy-n-methyloxolane-2-carboxamide Chemical compound O[C@@H]1[C@H](N)[C@@H](C(=O)NC)O[C@H]1N1C2=NC=NC(NCC=3C(=CC=C(F)C=3)OCC=3C=CC=CC=3)=C2N=C1 JAKKCOVQWXMHGR-BINBFKAUSA-N 0.000 description 1
OEIAEKKVBXUURQ-NDFWCKIISA-N (2s,3s,4r,5r)-3-amino-5-[6-[1-(5-chloro-2-phenylmethoxyphenyl)ethylamino]purin-9-yl]-4-hydroxy-n-methyloxolane-2-carboxamide Chemical compound O[C@@H]1[C@H](N)[C@@H](C(=O)NC)O[C@H]1N1C2=NC=NC(NC(C)C=3C(=CC=C(Cl)C=3)OCC=3C=CC=CC=3)=C2N=C1 OEIAEKKVBXUURQ-NDFWCKIISA-N 0.000 description 1
URICUAVGJPWILX-GGISIDAXSA-N (2s,3s,4r,5r)-3-amino-5-[6-[[2-(1,3-benzothiazol-2-ylmethoxy)-5-chlorophenyl]methylamino]purin-9-yl]-4-hydroxy-n-methyloxolane-2-carboxamide Chemical compound O[C@@H]1[C@H](N)[C@@H](C(=O)NC)O[C@H]1N1C2=NC=NC(NCC=3C(=CC=C(Cl)C=3)OCC=3SC4=CC=CC=C4N=3)=C2N=C1 URICUAVGJPWILX-GGISIDAXSA-N 0.000 description 1
MDYVPEARWPVKDR-ONLLFZDPSA-N (2s,3s,4r,5r)-3-amino-5-[6-[[2-(1-benzofuran-2-ylmethoxy)-5-chlorophenyl]methylamino]purin-9-yl]-4-hydroxy-n-methyloxolane-2-carboxamide Chemical compound O[C@@H]1[C@H](N)[C@@H](C(=O)NC)O[C@H]1N1C2=NC=NC(NCC=3C(=CC=C(Cl)C=3)OCC=3OC4=CC=CC=C4C=3)=C2N=C1 MDYVPEARWPVKDR-ONLLFZDPSA-N 0.000 description 1
YDUKIINBZMKEPQ-NCLAMWEWSA-N (2s,3s,4r,5r)-3-amino-5-[6-[[2-(2-amino-2-oxoethoxy)-5-chlorophenyl]methylamino]purin-9-yl]-4-hydroxy-n-methyloxolane-2-carboxamide Chemical compound O[C@@H]1[C@H](N)[C@@H](C(=O)NC)O[C@H]1N1C2=NC=NC(NCC=3C(=CC=C(Cl)C=3)OCC(N)=O)=C2N=C1 YDUKIINBZMKEPQ-NCLAMWEWSA-N 0.000 description 1
GDKXEKXFHYRBFK-GGISIDAXSA-N (2s,3s,4r,5r)-3-amino-5-[6-[[2-(2-anilino-2-oxoethoxy)-5-chlorophenyl]methylamino]purin-9-yl]-4-hydroxy-n-methyloxolane-2-carboxamide Chemical compound O[C@@H]1[C@H](N)[C@@H](C(=O)NC)O[C@H]1N1C2=NC=NC(NCC=3C(=CC=C(Cl)C=3)OCC(=O)NC=3C=CC=CC=3)=C2N=C1 GDKXEKXFHYRBFK-GGISIDAXSA-N 0.000 description 1
DXYVTUBLTMFQNG-ONLLFZDPSA-N (2s,3s,4r,5r)-3-amino-5-[6-[[2-[2-(benzylamino)-2-oxoethoxy]-5-chlorophenyl]methylamino]purin-9-yl]-4-hydroxy-n-methyloxolane-2-carboxamide Chemical compound O[C@@H]1[C@H](N)[C@@H](C(=O)NC)O[C@H]1N1C2=NC=NC(NCC=3C(=CC=C(Cl)C=3)OCC(=O)NCC=3C=CC=CC=3)=C2N=C1 DXYVTUBLTMFQNG-ONLLFZDPSA-N 0.000 description 1
WNQKGTWUHOWKHJ-KANGHSEISA-N (2s,3s,4r,5r)-3-amino-5-[6-[[5-chloro-2-(1,3-thiazol-2-ylmethoxy)phenyl]methylamino]purin-9-yl]-4-hydroxy-n-methyloxolane-2-carboxamide Chemical compound O[C@@H]1[C@H](N)[C@@H](C(=O)NC)O[C@H]1N1C2=NC=NC(NCC=3C(=CC=C(Cl)C=3)OCC=3SC=CN=3)=C2N=C1 WNQKGTWUHOWKHJ-KANGHSEISA-N 0.000 description 1
IHOXSZXXSOIJAN-NCLAMWEWSA-N (2s,3s,4r,5r)-3-amino-5-[6-[[5-chloro-2-(cyanomethoxy)phenyl]methylamino]purin-9-yl]-4-hydroxy-n-methyloxolane-2-carboxamide Chemical compound O[C@@H]1[C@H](N)[C@@H](C(=O)NC)O[C@H]1N1C2=NC=NC(NCC=3C(=CC=C(Cl)C=3)OCC#N)=C2N=C1 IHOXSZXXSOIJAN-NCLAMWEWSA-N 0.000 description 1
GGUYRWWJVCDMOA-QLBZUPSYSA-N (2s,3s,4r,5r)-3-amino-5-[6-[[5-chloro-2-(cyclopentylmethoxy)phenyl]methylamino]purin-9-yl]-4-hydroxy-n-methyloxolane-2-carboxamide Chemical compound O[C@@H]1[C@H](N)[C@@H](C(=O)NC)O[C@H]1N1C2=NC=NC(NCC=3C(=CC=C(Cl)C=3)OCC3CCCC3)=C2N=C1 GGUYRWWJVCDMOA-QLBZUPSYSA-N 0.000 description 1
XZNLUSYUSJIGHK-QYUDBREXSA-N (2s,3s,4r,5r)-3-amino-5-[6-[[5-chloro-2-(furan-2-ylmethoxy)phenyl]methylamino]purin-9-yl]-4-hydroxy-n-methyloxolane-2-carboxamide Chemical compound O[C@@H]1[C@H](N)[C@@H](C(=O)NC)O[C@H]1N1C2=NC=NC(NCC=3C(=CC=C(Cl)C=3)OCC=3OC=CC=3)=C2N=C1 XZNLUSYUSJIGHK-QYUDBREXSA-N 0.000 description 1
FKNPFYFSCFOGFA-QLBZUPSYSA-N (2s,3s,4r,5r)-3-amino-5-[6-[[5-chloro-2-(pyridin-3-ylmethoxy)phenyl]methylamino]purin-9-yl]-4-hydroxy-n-methyloxolane-2-carboxamide Chemical compound O[C@@H]1[C@H](N)[C@@H](C(=O)NC)O[C@H]1N1C2=NC=NC(NCC=3C(=CC=C(Cl)C=3)OCC=3C=NC=CC=3)=C2N=C1 FKNPFYFSCFOGFA-QLBZUPSYSA-N 0.000 description 1
GBTOWKCEUJOLBU-QYUDBREXSA-N (2s,3s,4r,5r)-3-amino-5-[6-[[5-chloro-2-(thiophen-2-ylmethoxy)phenyl]methylamino]purin-9-yl]-4-hydroxy-n-methyloxolane-2-carboxamide Chemical compound O[C@@H]1[C@H](N)[C@@H](C(=O)NC)O[C@H]1N1C2=NC=NC(NCC=3C(=CC=C(Cl)C=3)OCC=3SC=CC=3)=C2N=C1 GBTOWKCEUJOLBU-QYUDBREXSA-N 0.000 description 1
BEMSVPASVFTXHV-ONLLFZDPSA-N (2s,3s,4r,5r)-3-amino-5-[6-[[5-chloro-2-[(2,5-dimethoxyphenyl)methoxy]phenyl]methylamino]purin-9-yl]-4-hydroxy-n-methyloxolane-2-carboxamide Chemical compound O[C@@H]1[C@H](N)[C@@H](C(=O)NC)O[C@H]1N1C2=NC=NC(NCC=3C(=CC=C(Cl)C=3)OCC=3C(=CC=C(OC)C=3)OC)=C2N=C1 BEMSVPASVFTXHV-ONLLFZDPSA-N 0.000 description 1
GYPIFCRHPVNILU-BINBFKAUSA-N (2s,3s,4r,5r)-3-amino-5-[6-[[5-chloro-2-[(2-chlorophenyl)methoxy]phenyl]methylamino]purin-9-yl]-4-hydroxy-n-methyloxolane-2-carboxamide Chemical compound O[C@@H]1[C@H](N)[C@@H](C(=O)NC)O[C@H]1N1C2=NC=NC(NCC=3C(=CC=C(Cl)C=3)OCC=3C(=CC=CC=3)Cl)=C2N=C1 GYPIFCRHPVNILU-BINBFKAUSA-N 0.000 description 1
GUHXJCXUZIZXJF-GGISIDAXSA-N (2s,3s,4r,5r)-3-amino-5-[6-[[5-chloro-2-[(2-methylphenyl)methoxy]phenyl]methylamino]purin-9-yl]-4-hydroxy-n-methyloxolane-2-carboxamide Chemical compound O[C@@H]1[C@H](N)[C@@H](C(=O)NC)O[C@H]1N1C2=NC=NC(NCC=3C(=CC=C(Cl)C=3)OCC=3C(=CC=CC=3)C)=C2N=C1 GUHXJCXUZIZXJF-GGISIDAXSA-N 0.000 description 1
XRXJKBYJSOWMIP-BINBFKAUSA-N (2s,3s,4r,5r)-3-amino-5-[6-[[5-chloro-2-[(3-chlorophenyl)methoxy]phenyl]methylamino]purin-9-yl]-4-hydroxy-n-methyloxolane-2-carboxamide Chemical compound O[C@@H]1[C@H](N)[C@@H](C(=O)NC)O[C@H]1N1C2=NC=NC(NCC=3C(=CC=C(Cl)C=3)OCC=3C=C(Cl)C=CC=3)=C2N=C1 XRXJKBYJSOWMIP-BINBFKAUSA-N 0.000 description 1
OFBHGWDBBXSAHE-GGISIDAXSA-N (2s,3s,4r,5r)-3-amino-5-[6-[[5-chloro-2-[(3-methylphenyl)methoxy]phenyl]methylamino]purin-9-yl]-4-hydroxy-n-methyloxolane-2-carboxamide Chemical compound O[C@@H]1[C@H](N)[C@@H](C(=O)NC)O[C@H]1N1C2=NC=NC(NCC=3C(=CC=C(Cl)C=3)OCC=3C=C(C)C=CC=3)=C2N=C1 OFBHGWDBBXSAHE-GGISIDAXSA-N 0.000 description 1
JISBDVTUSBPLTE-BINBFKAUSA-N (2s,3s,4r,5r)-3-amino-5-[6-[[5-chloro-2-[(4-chlorophenyl)methoxy]phenyl]methylamino]purin-9-yl]-4-hydroxy-n-methyloxolane-2-carboxamide Chemical compound O[C@@H]1[C@H](N)[C@@H](C(=O)NC)O[C@H]1N1C2=NC=NC(NCC=3C(=CC=C(Cl)C=3)OCC=3C=CC(Cl)=CC=3)=C2N=C1 JISBDVTUSBPLTE-BINBFKAUSA-N 0.000 description 1
GAWAIWANZPGYPN-GGISIDAXSA-N (2s,3s,4r,5r)-3-amino-5-[6-[[5-chloro-2-[(4-methylphenyl)methoxy]phenyl]methylamino]purin-9-yl]-4-hydroxy-n-methyloxolane-2-carboxamide Chemical compound O[C@@H]1[C@H](N)[C@@H](C(=O)NC)O[C@H]1N1C2=NC=NC(NCC=3C(=CC=C(Cl)C=3)OCC=3C=CC(C)=CC=3)=C2N=C1 GAWAIWANZPGYPN-GGISIDAXSA-N 0.000 description 1
NCQVGJPYCYPKHT-GGISIDAXSA-N (2s,3s,4r,5r)-3-amino-5-[6-[[5-chloro-2-[2-(cyclohexylamino)-2-oxoethoxy]phenyl]methylamino]purin-9-yl]-4-hydroxy-n-methyloxolane-2-carboxamide Chemical compound O[C@@H]1[C@H](N)[C@@H](C(=O)NC)O[C@H]1N1C2=NC=NC(NCC=3C(=CC=C(Cl)C=3)OCC(=O)NC3CCCCC3)=C2N=C1 NCQVGJPYCYPKHT-GGISIDAXSA-N 0.000 description 1
GFFYCICHBUDBEM-QYUDBREXSA-N (2s,3s,4r,5r)-3-amino-5-[6-[[5-chloro-2-[2-(cyclopropylamino)-2-oxoethoxy]phenyl]methylamino]purin-9-yl]-4-hydroxy-n-methyloxolane-2-carboxamide Chemical compound O[C@@H]1[C@H](N)[C@@H](C(=O)NC)O[C@H]1N1C2=NC=NC(NCC=3C(=CC=C(Cl)C=3)OCC(=O)NC3CC3)=C2N=C1 GFFYCICHBUDBEM-QYUDBREXSA-N 0.000 description 1
XHVHHONQDRULTA-KANGHSEISA-N (2s,3s,4r,5r)-3-amino-5-[6-[[5-chloro-2-[2-(dimethylamino)-2-oxoethoxy]phenyl]methylamino]purin-9-yl]-4-hydroxy-n-methyloxolane-2-carboxamide Chemical compound O[C@@H]1[C@H](N)[C@@H](C(=O)NC)O[C@H]1N1C2=NC=NC(NCC=3C(=CC=C(Cl)C=3)OCC(=O)N(C)C)=C2N=C1 XHVHHONQDRULTA-KANGHSEISA-N 0.000 description 1
VCNDJDRVUGHRDV-GGISIDAXSA-N (2s,3s,4r,5r)-3-amino-5-[6-[[5-chloro-2-[2-(dipropylamino)-2-oxoethoxy]phenyl]methylamino]purin-9-yl]-4-hydroxy-n-methyloxolane-2-carboxamide Chemical compound CCCN(CCC)C(=O)COC1=CC=C(Cl)C=C1CNC1=NC=NC2=C1N=CN2[C@H]1[C@H](O)[C@H](N)[C@@H](C(=O)NC)O1 VCNDJDRVUGHRDV-GGISIDAXSA-N 0.000 description 1
QOPWJIRBQFEADC-YHXHNGJMSA-N (2s,3s,4r,5r)-3-amino-5-[6-[[5-chloro-2-[2-(methylamino)-2-oxoethoxy]phenyl]methylamino]purin-9-yl]-4-hydroxy-n-methyloxolane-2-carboxamide Chemical compound CNC(=O)COC1=CC=C(Cl)C=C1CNC1=NC=NC2=C1N=CN2[C@H]1[C@H](O)[C@H](N)[C@@H](C(=O)NC)O1 QOPWJIRBQFEADC-YHXHNGJMSA-N 0.000 description 1
BPJLFAXEOFSWGH-DSZDGCDSSA-N (2s,3s,4r,5r)-3-amino-5-[6-[[5-chloro-2-[2-oxo-2-(2-phenylethylamino)ethoxy]phenyl]methylamino]purin-9-yl]-4-hydroxy-n-methyloxolane-2-carboxamide Chemical compound O[C@@H]1[C@H](N)[C@@H](C(=O)NC)O[C@H]1N1C2=NC=NC(NCC=3C(=CC=C(Cl)C=3)OCC(=O)NCCC=3C=CC=CC=3)=C2N=C1 BPJLFAXEOFSWGH-DSZDGCDSSA-N 0.000 description 1
WAAPEIZFCHNLKK-UFBFGSQYSA-N (2s,4s)-6-fluoro-2',5'-dioxospiro[2,3-dihydrochromene-4,4'-imidazolidine]-2-carboxamide Chemical compound C([C@H](OC1=CC=C(F)C=C11)C(=O)N)[C@@]21NC(=O)NC2=O WAAPEIZFCHNLKK-UFBFGSQYSA-N 0.000 description 1
SRJRJOYFPZRDNH-NSHDSACASA-N (4s)-6-fluorospiro[3h-chromene-4,5'-imidazolidine]-2,4'-dione Chemical compound C12=CC(F)=CC=C2OC(=O)C[C@@]21NCNC2=O SRJRJOYFPZRDNH-NSHDSACASA-N 0.000 description 1
125000000229 (C1-C4)alkoxy group Chemical group 0.000 description 1
125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical compound CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 description 1
PVHUJELLJLJGLN-INIZCTEOSA-N (S)-nitrendipine Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC([N+]([O-])=O)=C1 PVHUJELLJLJGLN-INIZCTEOSA-N 0.000 description 1
125000005988 1,1-dioxo-thiomorpholinyl group Chemical group 0.000 description 1
125000004502 1,2,3-oxadiazolyl group Chemical group 0.000 description 1
125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 description 1
125000001376 1,2,4-triazolyl group Chemical group N1N=C(N=C1)* 0.000 description 1
125000004506 1,2,5-oxadiazolyl group Chemical group 0.000 description 1
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
UUOJIACWOAYWEZ-UHFFFAOYSA-N 1-(tert-butylamino)-3-[(2-methyl-1H-indol-4-yl)oxy]propan-2-yl benzoate Chemical compound C1=CC=C2NC(C)=CC2=C1OCC(CNC(C)(C)C)OC(=O)C1=CC=CC=C1 UUOJIACWOAYWEZ-UHFFFAOYSA-N 0.000 description 1
ZGEGCLOFRBLKSE-UHFFFAOYSA-N 1-Heptene Chemical group CCCCCC=C ZGEGCLOFRBLKSE-UHFFFAOYSA-N 0.000 description 1
ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
BHKKSKOHRFHHIN-MRVPVSSYSA-N 1-[[2-[(1R)-1-aminoethyl]-4-chlorophenyl]methyl]-2-sulfanylidene-5H-pyrrolo[3,2-d]pyrimidin-4-one Chemical compound N[C@H](C)C1=C(CN2C(NC(C3=C2C=CN3)=O)=S)C=CC(=C1)Cl BHKKSKOHRFHHIN-MRVPVSSYSA-N 0.000 description 1
NQRLUVCEUCAHST-UHFFFAOYSA-N 1-chloroindole-2-carboxylic acid Chemical compound C1=CC=C2N(Cl)C(C(=O)O)=CC2=C1 NQRLUVCEUCAHST-UHFFFAOYSA-N 0.000 description 1
125000005976 1-phenylethyloxy group Chemical group 0.000 description 1
125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
125000005955 1H-indazolyl group Chemical group 0.000 description 1
FYDPXVSFSSBHGW-UHFFFAOYSA-N 2,7-difluoro-4-methoxyspiro[fluorene-9,5'-imidazolidine]-2',4'-dione Chemical compound COC1=CC(F)=CC2=C1C1=CC=C(F)C=C1C21NC(=O)NC1=O FYDPXVSFSSBHGW-UHFFFAOYSA-N 0.000 description 1
QCCHBHSAIQIQGO-UHFFFAOYSA-N 2,7-difluorospiro[fluorene-9,5'-imidazolidine]-2',4'-dione Chemical compound C12=CC(F)=CC=C2C2=CC=C(F)C=C2C21NC(=O)NC2=O QCCHBHSAIQIQGO-UHFFFAOYSA-N 0.000 description 1
SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 1
ZEDQLIHBPGNGEC-UHFFFAOYSA-N 2-(4-oxo-3h-phthalazin-1-yl)acetic acid Chemical compound C1=CC=C2C(CC(=O)O)=NNC(=O)C2=C1 ZEDQLIHBPGNGEC-UHFFFAOYSA-N 0.000 description 1
JKGLRGGCGUQNEX-UHFFFAOYSA-N 2-(chloromethyl)isoindole-1,3-dione Chemical compound C1=CC=C2C(=O)N(CCl)C(=O)C2=C1 JKGLRGGCGUQNEX-UHFFFAOYSA-N 0.000 description 1
QTAUUWSYRMVXFM-NCLAMWEWSA-N 2-[2-[[[9-[(2r,3r,4s,5s)-4-amino-3-hydroxy-5-(methylcarbamoyl)oxolan-2-yl]purin-6-yl]amino]methyl]-4-chlorophenoxy]acetic acid Chemical compound O[C@@H]1[C@H](N)[C@@H](C(=O)NC)O[C@H]1N1C2=NC=NC(NCC=3C(=CC=C(Cl)C=3)OCC(O)=O)=C2N=C1 QTAUUWSYRMVXFM-NCLAMWEWSA-N 0.000 description 1
SENYCISNFWIXIL-NCLAMWEWSA-N 2-[2-[[[9-[(2r,3r,4s,5s)-4-azido-3-hydroxy-5-(methylcarbamoyl)oxolan-2-yl]purin-6-yl]amino]methyl]-4-chlorophenoxy]acetic acid Chemical compound O[C@@H]1[C@H](N=[N+]=[N-])[C@@H](C(=O)NC)O[C@H]1N1C2=NC=NC(NCC=3C(=CC=C(Cl)C=3)OCC(O)=O)=C2N=C1 SENYCISNFWIXIL-NCLAMWEWSA-N 0.000 description 1
SENYCISNFWIXIL-UHFFFAOYSA-N 2-[2-[[[9-[4-azido-3-hydroxy-5-(methylcarbamoyl)oxolan-2-yl]purin-6-yl]amino]methyl]-4-chlorophenoxy]acetic acid Chemical compound OC1C(N=[N+]=[N-])C(C(=O)NC)OC1N1C2=NC=NC(NCC=3C(=CC=C(Cl)C=3)OCC(O)=O)=C2N=C1 SENYCISNFWIXIL-UHFFFAOYSA-N 0.000 description 1
XSHTXZXPLDNDKC-UHFFFAOYSA-N 2-[3-[(5,7-dichloro-1,3-benzothiazol-2-yl)methyl]-4-oxophthalazin-1-yl]acetic acid Chemical compound O=C1C2=CC=CC=C2C(CC(=O)O)=NN1CC1=NC2=CC(Cl)=CC(Cl)=C2S1 XSHTXZXPLDNDKC-UHFFFAOYSA-N 0.000 description 1
FTPBFNMYCGQFGU-UHFFFAOYSA-N 2-[3-[(5,7-dichloro-1,3-benzoxazol-2-yl)methyl]-4-oxophthalazin-1-yl]acetic acid Chemical compound O=C1C2=CC=CC=C2C(CC(=O)O)=NN1CC1=NC2=CC(Cl)=CC(Cl)=C2O1 FTPBFNMYCGQFGU-UHFFFAOYSA-N 0.000 description 1
KNWXUWPPDTZSFW-UHFFFAOYSA-N 2-[3-[(5,7-difluoro-1,3-benzothiazol-2-yl)methyl]-4-oxophthalazin-1-yl]acetic acid Chemical compound O=C1C2=CC=CC=C2C(CC(=O)O)=NN1CC1=NC2=CC(F)=CC(F)=C2S1 KNWXUWPPDTZSFW-UHFFFAOYSA-N 0.000 description 1
GDULRSFIHLMHJW-UHFFFAOYSA-N 2-[3-[(5,7-difluoro-1,3-benzoxazol-2-yl)methyl]-4-oxophthalazin-1-yl]acetic acid Chemical compound O=C1C2=CC=CC=C2C(CC(=O)O)=NN1CC1=NC2=CC(F)=CC(F)=C2O1 GDULRSFIHLMHJW-UHFFFAOYSA-N 0.000 description 1
LNCWRJYGGOAOMU-UHFFFAOYSA-N 2-[3-[(5-chloro-1,3-benzothiazol-2-yl)methyl]-4-oxophthalazin-1-yl]acetic acid Chemical compound O=C1C2=CC=CC=C2C(CC(=O)O)=NN1CC1=NC2=CC(Cl)=CC=C2S1 LNCWRJYGGOAOMU-UHFFFAOYSA-N 0.000 description 1
LURVWPRCGVAWKT-UHFFFAOYSA-N 2-[3-[(5-chloro-1,3-benzoxazol-2-yl)methyl]-4-oxophthalazin-1-yl]acetic acid Chemical compound O=C1C2=CC=CC=C2C(CC(=O)O)=NN1CC1=NC2=CC(Cl)=CC=C2O1 LURVWPRCGVAWKT-UHFFFAOYSA-N 0.000 description 1
WXNKRTWVLOSZPW-UHFFFAOYSA-N 2-[3-[(5-fluoro-1,3-benzoxazol-2-yl)methyl]-4-oxophthalazin-1-yl]acetic acid Chemical compound O=C1C2=CC=CC=C2C(CC(=O)O)=NN1CC1=NC2=CC(F)=CC=C2O1 WXNKRTWVLOSZPW-UHFFFAOYSA-N 0.000 description 1
DGCTZGDPGOMMNB-UHFFFAOYSA-N 2-[3-oxo-2,8-di(propan-2-yl)-1,4-benzoxazin-4-yl]acetic acid Chemical compound C1=CC=C2N(CC(O)=O)C(=O)C(C(C)C)OC2=C1C(C)C DGCTZGDPGOMMNB-UHFFFAOYSA-N 0.000 description 1
QKRGDZKQCDTVMW-UHFFFAOYSA-N 2-[4-oxo-3-[[5-(trifluoromethyl)-1,3-benzoxazol-2-yl]methyl]phthalazin-1-yl]acetic acid Chemical compound O=C1C2=CC=CC=C2C(CC(=O)O)=NN1CC1=NC2=CC(C(F)(F)F)=CC=C2O1 QKRGDZKQCDTVMW-UHFFFAOYSA-N 0.000 description 1
AJTVSSFTXWNIRG-UHFFFAOYSA-N 2-[bis(2-hydroxyethyl)amino]ethanesulfonic acid Chemical compound OCC[NH+](CCO)CCS([O-])(=O)=O AJTVSSFTXWNIRG-UHFFFAOYSA-N 0.000 description 1
125000004847 2-fluorobenzyl group Chemical group [H]C1=C([H])C(F)=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
JRGBXEJDIMXJAP-UHFFFAOYSA-N 2-fluorospiro[fluorene-9,5'-imidazolidine]-2',4'-dione Chemical compound C12=CC(F)=CC=C2C2=CC=CC=C2C21NC(=O)NC2=O JRGBXEJDIMXJAP-UHFFFAOYSA-N 0.000 description 1
SGUAFYQXFOLMHL-UHFFFAOYSA-N 2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide Chemical compound C=1C=C(O)C(C(N)=O)=CC=1C(O)CNC(C)CCC1=CC=CC=C1 SGUAFYQXFOLMHL-UHFFFAOYSA-N 0.000 description 1
125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
LSFUSOASNPIGHU-UHFFFAOYSA-N 3-azido-5-[6-[[5-chloro-2-[(3,5-dimethyl-1,2-oxazol-4-yl)methoxy]phenyl]methylamino]purin-9-yl]-4-hydroxy-n-methyloxolane-2-carboxamide Chemical compound OC1C(N=[N+]=[N-])C(C(=O)NC)OC1N1C2=NC=NC(NCC=3C(=CC=C(Cl)C=3)OCC3=C(ON=C3C)C)=C2N=C1 LSFUSOASNPIGHU-UHFFFAOYSA-N 0.000 description 1
125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 1
QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
229960000549 4-dimethylaminophenol Drugs 0.000 description 1
125000004195 4-methylpiperazin-1-yl group Chemical group [H]C([H])([H])N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 1
125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
102100036009 5'-AMP-activated protein kinase catalytic subunit alpha-2 Human genes 0.000 description 1
PITVZRMNFBGRFW-UHFFFAOYSA-N 5,6-dichloro-1h-indole-2-carboxylic acid Chemical compound ClC1=C(Cl)C=C2NC(C(=O)O)=CC2=C1 PITVZRMNFBGRFW-UHFFFAOYSA-N 0.000 description 1
125000004539 5-benzimidazolyl group Chemical group N1=CNC2=C1C=CC(=C2)* 0.000 description 1
NGHMKLRBKIPQRY-UHFFFAOYSA-N 5-butyl-n-(diaminomethylidene)-1-quinolin-5-ylpyrazole-4-carboxamide Chemical compound CCCCC1=C(C(=O)NC(N)=N)C=NN1C1=CC=CC2=NC=CC=C12 NGHMKLRBKIPQRY-UHFFFAOYSA-N 0.000 description 1
DTAVSMRHCWEHSS-UHFFFAOYSA-N 5-chloro-1h-indole Chemical compound ClC1=CC=C2N[C]=CC2=C1 DTAVSMRHCWEHSS-UHFFFAOYSA-N 0.000 description 1
CVICEEPAFUYBJG-UHFFFAOYSA-N 5-chloro-2,2-difluoro-1,3-benzodioxole Chemical group C1=C(Cl)C=C2OC(F)(F)OC2=C1 CVICEEPAFUYBJG-UHFFFAOYSA-N 0.000 description 1
125000004008 6 membered carbocyclic group Chemical group 0.000 description 1
102100031126 6-phosphogluconolactonase Human genes 0.000 description 1
108010029731 6-phosphogluconolactonase Proteins 0.000 description 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
101150007969 ADORA1 gene Proteins 0.000 description 1
101150046889 ADORA3 gene Proteins 0.000 description 1
108010011376 AMP-Activated Protein Kinases Proteins 0.000 description 1
102000014156 AMP-Activated Protein Kinases Human genes 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
229930024421 Adenine Natural products 0.000 description 1
108010060261 Adenosine A3 Receptor Proteins 0.000 description 1
102000008161 Adenosine A3 Receptor Human genes 0.000 description 1
229940122614 Adenosine receptor agonist Drugs 0.000 description 1
102000005590 Anaphylatoxin C5a Receptor Human genes 0.000 description 1
108010059426 Anaphylatoxin C5a Receptor Proteins 0.000 description 1
108010001478 Bacitracin Proteins 0.000 description 1
201000006474 Brain Ischemia Diseases 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
125000002853 C1-C4 hydroxyalkyl group Chemical group 0.000 description 1
PWQJASDYRGVGAC-BTPAMZMASA-N C1COCC1COC2=C(C=C(C=C2)Cl)CNC3=C4C(=NC=N3)N(C=N4)[C@H]5[C@@H]([C@@H]([C@H](O5)C(=O)O)N=[N+]=[N-])O Chemical compound C1COCC1COC2=C(C=C(C=C2)Cl)CNC3=C4C(=NC=N3)N(C=N4)[C@H]5[C@@H]([C@@H]([C@H](O5)C(=O)O)N=[N+]=[N-])O PWQJASDYRGVGAC-BTPAMZMASA-N 0.000 description 1
BUELMBFSPQNFIS-UHFFFAOYSA-N C=1(C=CC2=CCC=CC12)O Chemical compound C=1(C=CC2=CCC=CC12)O BUELMBFSPQNFIS-UHFFFAOYSA-N 0.000 description 1
YETMGQZXNMHJCX-UHFFFAOYSA-N CNN1C2=NC=NC(NCC(C=C(C=C3)Cl)=C3OCC(C(C3)NCCN3C3C4CC(C5)CC3CC5C4)=O)=C2N=C1.[N-]=[N+]=NC1C(C(O)=O)OCC1O Chemical compound CNN1C2=NC=NC(NCC(C=C(C=C3)Cl)=C3OCC(C(C3)NCCN3C3C4CC(C5)CC3CC5C4)=O)=C2N=C1.[N-]=[N+]=NC1C(C(O)=O)OCC1O YETMGQZXNMHJCX-UHFFFAOYSA-N 0.000 description 1
GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 1
101100008046 Caenorhabditis elegans cut-2 gene Proteins 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
102000011727 Caspases Human genes 0.000 description 1
108010076667 Caspases Proteins 0.000 description 1
206010008120 Cerebral ischaemia Diseases 0.000 description 1
206010008190 Cerebrovascular accident Diseases 0.000 description 1
JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
206010053567 Coagulopathies Diseases 0.000 description 1
102000008186 Collagen Human genes 0.000 description 1
108010035532 Collagen Proteins 0.000 description 1
108020004635 Complementary DNA Proteins 0.000 description 1
241000699802 Cricetulus griseus Species 0.000 description 1
206010011703 Cyanosis Diseases 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
208000007342 Diabetic Nephropathies Diseases 0.000 description 1
QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 description 1
GKQLYSROISKDLL-UHFFFAOYSA-N EEDQ Chemical compound C1=CC=C2N(C(=O)OCC)C(OCC)C=CC2=C1 GKQLYSROISKDLL-UHFFFAOYSA-N 0.000 description 1
239000004097 EU approved flavor enhancer Substances 0.000 description 1
102000002045 Endothelin Human genes 0.000 description 1
108050009340 Endothelin Proteins 0.000 description 1
UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
208000018522 Gastrointestinal disease Diseases 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
239000001828 Gelatine Substances 0.000 description 1
229940121931 Gluconeogenesis inhibitor Drugs 0.000 description 1
108010018962 Glucosephosphate Dehydrogenase Proteins 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
206010018985 Haemorrhage intracranial Diseases 0.000 description 1
102000001554 Hemoglobins Human genes 0.000 description 1
108010054147 Hemoglobins Proteins 0.000 description 1
208000032456 Hemorrhagic Shock Diseases 0.000 description 1
208000016988 Hemorrhagic Stroke Diseases 0.000 description 1
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
101000783681 Homo sapiens 5'-AMP-activated protein kinase catalytic subunit alpha-2 Proteins 0.000 description 1
101000783645 Homo sapiens Adenosine receptor A3 Proteins 0.000 description 1
206010020565 Hyperaemia Diseases 0.000 description 1
206010020772 Hypertension Diseases 0.000 description 1
206010022489 Insulin Resistance Diseases 0.000 description 1
208000008574 Intracranial Hemorrhages Diseases 0.000 description 1
108010044467 Isoenzymes Proteins 0.000 description 1
KLDXJTOLSGUMSJ-JGWLITMVSA-N Isosorbide Chemical compound O[C@@H]1CO[C@@H]2[C@@H](O)CO[C@@H]21 KLDXJTOLSGUMSJ-JGWLITMVSA-N 0.000 description 1
239000012839 Krebs-Henseleit buffer Substances 0.000 description 1
JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
108010081805 Malonyl-CoA decarboxylase Proteins 0.000 description 1
102100029461 Malonyl-CoA decarboxylase, mitochondrial Human genes 0.000 description 1
229910021380 Manganese Chloride Inorganic materials 0.000 description 1
GLFNIEUTAYBVOC-UHFFFAOYSA-L Manganese chloride Chemical compound Cl[Mn]Cl GLFNIEUTAYBVOC-UHFFFAOYSA-L 0.000 description 1
240000003183 Manihot esculenta Species 0.000 description 1
235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
102000018697 Membrane Proteins Human genes 0.000 description 1
108010052285 Membrane Proteins Proteins 0.000 description 1
102000016943 Muramidase Human genes 0.000 description 1
108010014251 Muramidase Proteins 0.000 description 1
241001180649 Myrcia group Species 0.000 description 1
TVQYSFQSMXNANA-RWRPPVFZSA-N N(=[N+]=[N-])[C@@H]1[C@H](O[C@H]([C@@H]1O)N1C2=NC=NC(=C2N=C1)NCC1=C(C=CC(=C1)Cl)OCC(=O)N1CC(NC(C1)C)C)C(=O)O Chemical compound N(=[N+]=[N-])[C@@H]1[C@H](O[C@H]([C@@H]1O)N1C2=NC=NC(=C2N=C1)NCC1=C(C=CC(=C1)Cl)OCC(=O)N1CC(NC(C1)C)C)C(=O)O TVQYSFQSMXNANA-RWRPPVFZSA-N 0.000 description 1
SEWOVKZVCBOWSV-XIXAVDCQSA-N N(=[N+]=[N-])[C@@H]1[C@H](O[C@H]([C@@H]1O)N1C2=NC=NC(=C2N=C1)NCC1=C(C=CC(=C1)Cl)OCC(=O)N1CCC(CC1)N(C)C)C(=O)O Chemical compound N(=[N+]=[N-])[C@@H]1[C@H](O[C@H]([C@@H]1O)N1C2=NC=NC(=C2N=C1)NCC1=C(C=CC(=C1)Cl)OCC(=O)N1CCC(CC1)N(C)C)C(=O)O SEWOVKZVCBOWSV-XIXAVDCQSA-N 0.000 description 1
CIDSHIQNNMMFST-JBYGMCGMSA-N N(=[N+]=[N-])[C@@H]1[C@H](O[C@H]([C@@H]1O)N1C2=NC=NC(=C2N=C1)NCC1=C(C=CC(=C1)Cl)OCC(=O)N1CCC(CC1)N)C(=O)O Chemical compound N(=[N+]=[N-])[C@@H]1[C@H](O[C@H]([C@@H]1O)N1C2=NC=NC(=C2N=C1)NCC1=C(C=CC(=C1)Cl)OCC(=O)N1CCC(CC1)N)C(=O)O CIDSHIQNNMMFST-JBYGMCGMSA-N 0.000 description 1
GSSTWHASKQNDBL-TYDNGALESA-N N(=[N+]=[N-])[C@@H]1[C@H](O[C@H]([C@@H]1O)N1C2=NC=NC(=C2N=C1)NCC1=C(C=CC(=C1)Cl)OCC(=O)N1CCC(CC1)NC(=O)OC(C)(C)C)C(=O)O Chemical compound N(=[N+]=[N-])[C@@H]1[C@H](O[C@H]([C@@H]1O)N1C2=NC=NC(=C2N=C1)NCC1=C(C=CC(=C1)Cl)OCC(=O)N1CCC(CC1)NC(=O)OC(C)(C)C)C(=O)O GSSTWHASKQNDBL-TYDNGALESA-N 0.000 description 1
OPUBKGAYKWPPFE-XIXAVDCQSA-N N(=[N+]=[N-])[C@@H]1[C@H](O[C@H]([C@@H]1O)N1C2=NC=NC(=C2N=C1)NCC1=C(C=CC(=C1)Cl)OCC(=O)N1CCN(CC1)C(C)C)C(=O)O Chemical compound N(=[N+]=[N-])[C@@H]1[C@H](O[C@H]([C@@H]1O)N1C2=NC=NC(=C2N=C1)NCC1=C(C=CC(=C1)Cl)OCC(=O)N1CCN(CC1)C(C)C)C(=O)O OPUBKGAYKWPPFE-XIXAVDCQSA-N 0.000 description 1
OLHTWWGMYIAKFE-JBYGMCGMSA-N N(=[N+]=[N-])[C@@H]1[C@H](O[C@H]([C@@H]1O)N1C2=NC=NC(=C2N=C1)NCC1=C(C=CC(=C1)Cl)OCC(=O)N1CCN(CC1)C)C(=O)O Chemical compound N(=[N+]=[N-])[C@@H]1[C@H](O[C@H]([C@@H]1O)N1C2=NC=NC(=C2N=C1)NCC1=C(C=CC(=C1)Cl)OCC(=O)N1CCN(CC1)C)C(=O)O OLHTWWGMYIAKFE-JBYGMCGMSA-N 0.000 description 1
PHPNFLNRXVTUFR-XIXAVDCQSA-N N(=[N+]=[N-])[C@@H]1[C@H](O[C@H]([C@@H]1O)N1C2=NC=NC(=C2N=C1)NCC1=C(C=CC(=C1)Cl)OCC(=O)N1CCN(CC1)C1CC1)C(=O)O Chemical compound N(=[N+]=[N-])[C@@H]1[C@H](O[C@H]([C@@H]1O)N1C2=NC=NC(=C2N=C1)NCC1=C(C=CC(=C1)Cl)OCC(=O)N1CCN(CC1)C1CC1)C(=O)O PHPNFLNRXVTUFR-XIXAVDCQSA-N 0.000 description 1
LNVJHGYBKKQUKP-DWIHMJRXSA-N N(=[N+]=[N-])[C@@H]1[C@H](O[C@H]([C@@H]1O)N1C2=NC=NC(=C2N=C1)NCC1=C(C=CC(=C1)Cl)OCC(=O)N1CCN(CC1)C1CCCCC1)C(=O)O Chemical compound N(=[N+]=[N-])[C@@H]1[C@H](O[C@H]([C@@H]1O)N1C2=NC=NC(=C2N=C1)NCC1=C(C=CC(=C1)Cl)OCC(=O)N1CCN(CC1)C1CCCCC1)C(=O)O LNVJHGYBKKQUKP-DWIHMJRXSA-N 0.000 description 1
BADBUYQQIZSGRY-KKMBPYAXSA-N N(=[N+]=[N-])[C@@H]1[C@H](O[C@H]([C@@H]1O)N1C2=NC=NC(=C2N=C1)NCC1=C(C=CC(=C1)Cl)OCC(NCCN1CCOCC1)=O)C(=O)O Chemical compound N(=[N+]=[N-])[C@@H]1[C@H](O[C@H]([C@@H]1O)N1C2=NC=NC(=C2N=C1)NCC1=C(C=CC(=C1)Cl)OCC(NCCN1CCOCC1)=O)C(=O)O BADBUYQQIZSGRY-KKMBPYAXSA-N 0.000 description 1
OIIQUNGCLYJNCO-JBYGMCGMSA-N N(=[N+]=[N-])[C@@H]1[C@H](O[C@H]([C@@H]1O)N1C2=NC=NC(=C2N=C1)NCC1=C(C=CC(=C1)Cl)OCC1=C(OC(=C1)C)C)C(=O)O Chemical compound N(=[N+]=[N-])[C@@H]1[C@H](O[C@H]([C@@H]1O)N1C2=NC=NC(=C2N=C1)NCC1=C(C=CC(=C1)Cl)OCC1=C(OC(=C1)C)C)C(=O)O OIIQUNGCLYJNCO-JBYGMCGMSA-N 0.000 description 1
KMKWIIRDWYUNLM-BINBFKAUSA-N N(=[N+]=[N-])[C@H]1[C@H]([C@@H](O[C@@H]1C(NC)=O)N1C2=NC=NC(=C2N=C1)NCC1=C(OCC(=O)N2CCC(CC2)C(=O)O)C=CC(=C1)Cl)O Chemical compound N(=[N+]=[N-])[C@H]1[C@H]([C@@H](O[C@@H]1C(NC)=O)N1C2=NC=NC(=C2N=C1)NCC1=C(OCC(=O)N2CCC(CC2)C(=O)O)C=CC(=C1)Cl)O KMKWIIRDWYUNLM-BINBFKAUSA-N 0.000 description 1
XKLMZUWKNUAPSZ-UHFFFAOYSA-N N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl}acetamide Chemical compound COC1=CC=CC=C1OCC(O)CN1CCN(CC(=O)NC=2C(=CC=CC=2C)C)CC1 XKLMZUWKNUAPSZ-UHFFFAOYSA-N 0.000 description 1
108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
125000005118 N-alkylcarbamoyl group Chemical group 0.000 description 1
MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
238000012565 NMR experiment Methods 0.000 description 1
HJAVFTDIPIXMER-JBYGMCGMSA-N N[C@@H]1[C@H](O[C@H]([C@@H]1O)N1C2=NC=NC(=C2N=C1)NCC1=C(C=CC(=C1)Cl)OCC(=O)N1CCC(CC1)N)C(=O)O Chemical compound N[C@@H]1[C@H](O[C@H]([C@@H]1O)N1C2=NC=NC(=C2N=C1)NCC1=C(C=CC(=C1)Cl)OCC(=O)N1CCC(CC1)N)C(=O)O HJAVFTDIPIXMER-JBYGMCGMSA-N 0.000 description 1
WFUPTZAIOMAOSE-KKMBPYAXSA-N N[C@@H]1[C@H](O[C@H]([C@@H]1O)N1C2=NC=NC(=C2N=C1)NCC1=C(C=CC(=C1)Cl)OCC(=O)N1CCC(CC1)NC)C(=O)O Chemical compound N[C@@H]1[C@H](O[C@H]([C@@H]1O)N1C2=NC=NC(=C2N=C1)NCC1=C(C=CC(=C1)Cl)OCC(=O)N1CCC(CC1)NC)C(=O)O WFUPTZAIOMAOSE-KKMBPYAXSA-N 0.000 description 1
OMNNCSJNEMGUTI-DWIHMJRXSA-N N[C@@H]1[C@H](O[C@H]([C@@H]1O)N1C2=NC=NC(=C2N=C1)NCC1=C(C=CC(=C1)Cl)OCC(=O)N1CCN(CC1)C1CCCCC1)C(=O)O Chemical compound N[C@@H]1[C@H](O[C@H]([C@@H]1O)N1C2=NC=NC(=C2N=C1)NCC1=C(C=CC(=C1)Cl)OCC(=O)N1CCN(CC1)C1CCCCC1)C(=O)O OMNNCSJNEMGUTI-DWIHMJRXSA-N 0.000 description 1
FFTMZRSHOZYSIL-KKMBPYAXSA-N N[C@@H]1[C@H](O[C@H]([C@@H]1O)N1C2=NC=NC(=C2N=C1)NCC1=C(C=CC(=C1)Cl)OCC(=O)N1CCN(CC1)CC)C(=O)O Chemical compound N[C@@H]1[C@H](O[C@H]([C@@H]1O)N1C2=NC=NC(=C2N=C1)NCC1=C(C=CC(=C1)Cl)OCC(=O)N1CCN(CC1)CC)C(=O)O FFTMZRSHOZYSIL-KKMBPYAXSA-N 0.000 description 1
JSMIURYNXWEHJD-YNFBMLRVSA-N N[C@@H]1[C@H](O[C@H]([C@@H]1O)N1C2=NC=NC(=C2N=C1)NCC1=C(C=CC(=C1)Cl)OCC(N1CCNCC1)=O)C(=O)O Chemical compound N[C@@H]1[C@H](O[C@H]([C@@H]1O)N1C2=NC=NC(=C2N=C1)NCC1=C(C=CC(=C1)Cl)OCC(N1CCNCC1)=O)C(=O)O JSMIURYNXWEHJD-YNFBMLRVSA-N 0.000 description 1
VGXFRDJGAUIRES-KKMBPYAXSA-N N[C@@H]1[C@H](O[C@H]([C@@H]1O)N1C2=NC=NC(=C2N=C1)NCC1=C(C=CC(=C1)Cl)OCC(NCCN1CCOCC1)=O)C(=O)O Chemical compound N[C@@H]1[C@H](O[C@H]([C@@H]1O)N1C2=NC=NC(=C2N=C1)NCC1=C(C=CC(=C1)Cl)OCC(NCCN1CCOCC1)=O)C(=O)O VGXFRDJGAUIRES-KKMBPYAXSA-N 0.000 description 1
KCZIFNOZVHLRNQ-DZIWXPPMSA-N N[C@@H]1[C@H](O[C@H]([C@@H]1O)N1C2=NC=NC(=C2N=C1)NCC1=C(C=CC(=C1)Cl)OCC1=C(N=NS1)C)C(=O)O Chemical compound N[C@@H]1[C@H](O[C@H]([C@@H]1O)N1C2=NC=NC(=C2N=C1)NCC1=C(C=CC(=C1)Cl)OCC1=C(N=NS1)C)C(=O)O KCZIFNOZVHLRNQ-DZIWXPPMSA-N 0.000 description 1
AFYZOHYKYPXLMZ-PTSPBZQHSA-N N[C@@H]1[C@H](O[C@H]([C@@H]1O)N1C2=NC=NC(=C2N=C1)NCC1=C(C=CC(=C1)Cl)OCC1=CC(=CC=C1)OCCN1CCOCC1)C(=O)O Chemical compound N[C@@H]1[C@H](O[C@H]([C@@H]1O)N1C2=NC=NC(=C2N=C1)NCC1=C(C=CC(=C1)Cl)OCC1=CC(=CC=C1)OCCN1CCOCC1)C(=O)O AFYZOHYKYPXLMZ-PTSPBZQHSA-N 0.000 description 1
MRGXRIPOCLAIBJ-BTPAMZMASA-N N[C@@H]1[C@H](O[C@H]([C@@H]1O)N1C2=NC=NC(=C2N=C1)NCC1=C(C=CC(=C1)Cl)OCC1COCC1)C(=O)O Chemical compound N[C@@H]1[C@H](O[C@H]([C@@H]1O)N1C2=NC=NC(=C2N=C1)NCC1=C(C=CC(=C1)Cl)OCC1COCC1)C(=O)O MRGXRIPOCLAIBJ-BTPAMZMASA-N 0.000 description 1
ZSXLTHGBZMVJIP-YNFBMLRVSA-N N[C@@H]1[C@H](O[C@H]([C@@H]1O)N1C2=NC=NC(=C2N=C1)NCC1=C(C=CC(=C1)Cl)OCC=1C(=NOC1C)C)C(=O)O Chemical compound N[C@@H]1[C@H](O[C@H]([C@@H]1O)N1C2=NC=NC(=C2N=C1)NCC1=C(C=CC(=C1)Cl)OCC=1C(=NOC1C)C)C(=O)O ZSXLTHGBZMVJIP-YNFBMLRVSA-N 0.000 description 1
229930193140 Neomycin Natural products 0.000 description 1
SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
241000121237 Nitrospirae Species 0.000 description 1
LFXWVKBMGRCIJI-WFBUOHSLSA-N O=S1(CN(CC1)C(CNC(=O)C=1NC2=CC=C(C=C2C1)Cl)=O)=O.C(C1=CC=CC=C1)[C@@H](C(=O)N1C[C@H]([C@H](C1)O)O)NC(=O)C=1NC2=CC=C(C=C2C1)Cl Chemical compound O=S1(CN(CC1)C(CNC(=O)C=1NC2=CC=C(C=C2C1)Cl)=O)=O.C(C1=CC=CC=C1)[C@@H](C(=O)N1C[C@H]([C@H](C1)O)O)NC(=O)C=1NC2=CC=C(C=C2C1)Cl LFXWVKBMGRCIJI-WFBUOHSLSA-N 0.000 description 1
241000283977 Oryctolagus Species 0.000 description 1
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
241000776450 PVC group Species 0.000 description 1
235000019483 Peanut oil Nutrition 0.000 description 1
229930182555 Penicillin Natural products 0.000 description 1
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
229940099471 Phosphodiesterase inhibitor Drugs 0.000 description 1
102000009569 Phosphoglucomutase Human genes 0.000 description 1
OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
UJEWTUDSLQGTOA-UHFFFAOYSA-N Piretanide Chemical compound C=1C=CC=CC=1OC=1C(S(=O)(=O)N)=CC(C(O)=O)=CC=1N1CCCC1 UJEWTUDSLQGTOA-UHFFFAOYSA-N 0.000 description 1
229920002873 Polyethylenimine Polymers 0.000 description 1
229940127315 Potassium Channel Openers Drugs 0.000 description 1
KDCGOANMDULRCW-UHFFFAOYSA-N Purine Natural products N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 1
102000053067 Pyruvate Dehydrogenase Acetyl-Transferring Kinase Human genes 0.000 description 1
239000007868 Raney catalyst Substances 0.000 description 1
NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 1
229910000564 Raney nickel Inorganic materials 0.000 description 1
206010038563 Reocclusion Diseases 0.000 description 1
206010063837 Reperfusion injury Diseases 0.000 description 1
229920005654 Sephadex Polymers 0.000 description 1
239000012507 Sephadex™ Substances 0.000 description 1
206010040047 Sepsis Diseases 0.000 description 1
244000000231 Sesamum indicum Species 0.000 description 1
206010049771 Shock haemorrhagic Diseases 0.000 description 1
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
244000061456 Solanum tuberosum Species 0.000 description 1
235000002595 Solanum tuberosum Nutrition 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
206010042434 Sudden death Diseases 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
108090000190 Thrombin Proteins 0.000 description 1
229920004890 Triton X-100 Polymers 0.000 description 1
239000013504 Triton X-100 Substances 0.000 description 1
108020005202 Viral DNA Proteins 0.000 description 1
241000700605 Viruses Species 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
HXXFSFRBOHSIMQ-UHFFFAOYSA-N [3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] dihydrogen phosphate Chemical compound OCC1OC(OP(O)(O)=O)C(O)C(O)C1O HXXFSFRBOHSIMQ-UHFFFAOYSA-N 0.000 description 1
YCSDQGWMRRXTBL-UHFFFAOYSA-N [4-azido-2-(6-chloropurin-9-yl)-5-(methylcarbamoyl)oxolan-3-yl] acetate Chemical compound CC(=O)OC1C(N=[N+]=[N-])C(C(=O)NC)OC1N1C2=NC=NC(Cl)=C2N=C1 YCSDQGWMRRXTBL-UHFFFAOYSA-N 0.000 description 1
ZHAFUINZIZIXFC-UHFFFAOYSA-N [9-(dimethylamino)-10-methylbenzo[a]phenoxazin-5-ylidene]azanium;chloride Chemical compound [Cl-].O1C2=CC(=[NH2+])C3=CC=CC=C3C2=NC2=C1C=C(N(C)C)C(C)=C2 ZHAFUINZIZIXFC-UHFFFAOYSA-N 0.000 description 1
101710159466 [Pyruvate dehydrogenase (acetyl-transferring)] kinase, mitochondrial Proteins 0.000 description 1
230000001133 acceleration Effects 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
229960002122 acebutolol Drugs 0.000 description 1
GOEMGAFJFRBGGG-UHFFFAOYSA-N acebutolol Chemical compound CCCC(=O)NC1=CC=C(OCC(O)CNC(C)C)C(C(C)=O)=C1 GOEMGAFJFRBGGG-UHFFFAOYSA-N 0.000 description 1
239000003377 acid catalyst Substances 0.000 description 1
238000005903 acid hydrolysis reaction Methods 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
229960000643 adenine Drugs 0.000 description 1
230000002411 adverse Effects 0.000 description 1
238000005273 aeration Methods 0.000 description 1
150000001299 aldehydes Chemical class 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
125000005085 alkoxycarbonylalkoxy group Chemical group 0.000 description 1
125000005078 alkoxycarbonylalkyl group Chemical group 0.000 description 1
150000003973 alkyl amines Chemical class 0.000 description 1
125000000278 alkyl amino alkyl group Chemical group 0.000 description 1
125000003806 alkyl carbonyl amino group Chemical group 0.000 description 1
239000002168 alkylating agent Substances 0.000 description 1
229940100198 alkylating agent Drugs 0.000 description 1
125000002947 alkylene group Chemical group 0.000 description 1
VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
230000001668 ameliorated effect Effects 0.000 description 1
XSDQTOBWRPYKKA-UHFFFAOYSA-N amiloride Chemical compound NC(=N)NC(=O)C1=NC(Cl)=C(N)N=C1N XSDQTOBWRPYKKA-UHFFFAOYSA-N 0.000 description 1
229960002576 amiloride Drugs 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 description 1
229960000528 amlodipine Drugs 0.000 description 1
XKMRRTOUMJRJIA-UHFFFAOYSA-N ammonia nh3 Chemical compound N.N XKMRRTOUMJRJIA-UHFFFAOYSA-N 0.000 description 1
235000019270 ammonium chloride Nutrition 0.000 description 1
239000011609 ammonium molybdate Substances 0.000 description 1
235000018660 ammonium molybdate Nutrition 0.000 description 1
APUPEJJSWDHEBO-UHFFFAOYSA-P ammonium molybdate Chemical compound [NH4+].[NH4+].[O-][Mo]([O-])(=O)=O APUPEJJSWDHEBO-UHFFFAOYSA-P 0.000 description 1
229940010552 ammonium molybdate Drugs 0.000 description 1
238000000540 analysis of variance Methods 0.000 description 1
150000008064 anhydrides Chemical class 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
150000001491 aromatic compounds Chemical class 0.000 description 1
230000004872 arterial blood pressure Effects 0.000 description 1
125000003118 aryl group Chemical group 0.000 description 1
229960002274 atenolol Drugs 0.000 description 1
238000000065 atmospheric pressure chemical ionisation Methods 0.000 description 1
230000001746 atrial effect Effects 0.000 description 1
125000002785 azepinyl group Chemical group 0.000 description 1
125000004566 azetidin-1-yl group Chemical group N1(CCC1)* 0.000 description 1
229960003071 bacitracin Drugs 0.000 description 1
229930184125 bacitracin Natural products 0.000 description 1
CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 description 1
229910052788 barium Inorganic materials 0.000 description 1
DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical group [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
210000004227 basal ganglia Anatomy 0.000 description 1
UPABQMWFWCMOFV-UHFFFAOYSA-N benethamine Chemical compound C=1C=CC=CC=1CNCCC1=CC=CC=C1 UPABQMWFWCMOFV-UHFFFAOYSA-N 0.000 description 1
125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
235000019445 benzyl alcohol Nutrition 0.000 description 1
150000005347 biaryls Chemical class 0.000 description 1
150000004283 biguanides Chemical class 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000004321 blink reflex Effects 0.000 description 1
230000008081 blood perfusion Effects 0.000 description 1
238000009530 blood pressure measurement Methods 0.000 description 1
210000004204 blood vessel Anatomy 0.000 description 1
229960001035 bopindolol Drugs 0.000 description 1
ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 1
238000009395 breeding Methods 0.000 description 1
230000001488 breeding effect Effects 0.000 description 1
239000012267 brine Substances 0.000 description 1
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
229910000019 calcium carbonate Inorganic materials 0.000 description 1
238000004364 calculation method Methods 0.000 description 1
FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 1
229960000830 captopril Drugs 0.000 description 1
125000002837 carbocyclic group Chemical group 0.000 description 1
229910002091 carbon monoxide Inorganic materials 0.000 description 1
PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 1
125000005111 carboxyalkoxy group Chemical group 0.000 description 1
150000001244 carboxylic acid anhydrides Chemical class 0.000 description 1
150000001735 carboxylic acids Chemical class 0.000 description 1
230000003293 cardioprotective effect Effects 0.000 description 1
230000005792 cardiovascular activity Effects 0.000 description 1
210000001715 carotid artery Anatomy 0.000 description 1
239000000969 carrier Substances 0.000 description 1
238000010531 catalytic reduction reaction Methods 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
239000006285 cell suspension Substances 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
235000010980 cellulose Nutrition 0.000 description 1
210000001627 cerebral artery Anatomy 0.000 description 1
210000003710 cerebral cortex Anatomy 0.000 description 1
230000008859 change Effects 0.000 description 1
229920001429 chelating resin Polymers 0.000 description 1
239000007795 chemical reaction product Substances 0.000 description 1
239000007810 chemical reaction solvent Substances 0.000 description 1
OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
229960001231 choline Drugs 0.000 description 1
239000007979 citrate buffer Substances 0.000 description 1
230000035602 clotting Effects 0.000 description 1
230000015271 coagulation Effects 0.000 description 1
238000005345 coagulation Methods 0.000 description 1
229920001436 collagen Polymers 0.000 description 1
238000004040 coloring Methods 0.000 description 1
238000004440 column chromatography Methods 0.000 description 1
230000000295 complement effect Effects 0.000 description 1
230000003750 conditioning effect Effects 0.000 description 1
238000001816 cooling Methods 0.000 description 1
ORTQZVOHEJQUHG-UHFFFAOYSA-L copper(II) chloride Chemical compound Cl[Cu]Cl ORTQZVOHEJQUHG-UHFFFAOYSA-L 0.000 description 1
238000012937 correction Methods 0.000 description 1
239000012043 crude product Substances 0.000 description 1
VMKJWLXVLHBJNK-UHFFFAOYSA-N cyanuric fluoride Chemical compound FC1=NC(F)=NC(F)=N1 VMKJWLXVLHBJNK-UHFFFAOYSA-N 0.000 description 1
125000000392 cycloalkenyl group Chemical group 0.000 description 1
125000001316 cycloalkyl alkyl group Chemical group 0.000 description 1
125000005112 cycloalkylalkoxy group Chemical group 0.000 description 1
125000000522 cyclooctenyl group Chemical group C1(=CCCCCCC1)* 0.000 description 1
125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
125000004855 decalinyl group Chemical group C1(CCCC2CCCCC12)* 0.000 description 1
239000003954 decarboxylase inhibitor Substances 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
229910052805 deuterium Inorganic materials 0.000 description 1
238000011161 development Methods 0.000 description 1
208000033679 diabetic kidney disease Diseases 0.000 description 1
230000035487 diastolic blood pressure Effects 0.000 description 1
229940120124 dichloroacetate Drugs 0.000 description 1
JXTHNDFMNIQAHM-UHFFFAOYSA-N dichloroacetic acid Chemical compound OC(=O)C(Cl)Cl JXTHNDFMNIQAHM-UHFFFAOYSA-N 0.000 description 1
ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
229940043237 diethanolamine Drugs 0.000 description 1
VLNZUSMTOFYNPS-UHFFFAOYSA-N diethylphosphorylformonitrile Chemical compound CCP(=O)(CC)C#N VLNZUSMTOFYNPS-UHFFFAOYSA-N 0.000 description 1
LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 description 1
229960005156 digoxin Drugs 0.000 description 1
LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 description 1
IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 1
MKRTXPORKIRPDG-UHFFFAOYSA-N diphenylphosphoryl azide Chemical compound C=1C=CC=CC=1P(=O)(N=[N+]=[N-])C1=CC=CC=C1 MKRTXPORKIRPDG-UHFFFAOYSA-N 0.000 description 1
238000006073 displacement reaction Methods 0.000 description 1
229940030606 diuretics Drugs 0.000 description 1
238000001647 drug administration Methods 0.000 description 1
239000000975 dye Substances 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
150000002085 enols Chemical group 0.000 description 1
CHNUOJQWGUIOLD-NFZZJPOKSA-N epalrestat Chemical compound C=1C=CC=CC=1\C=C(/C)\C=C1/SC(=S)N(CC(O)=O)C1=O CHNUOJQWGUIOLD-NFZZJPOKSA-N 0.000 description 1
229950010170 epalrestat Drugs 0.000 description 1
CHNUOJQWGUIOLD-UHFFFAOYSA-N epalrestate Natural products C=1C=CC=CC=1C=C(C)C=C1SC(=S)N(CC(O)=O)C1=O CHNUOJQWGUIOLD-UHFFFAOYSA-N 0.000 description 1
238000011067 equilibration Methods 0.000 description 1
210000003743 erythrocyte Anatomy 0.000 description 1
230000032050 esterification Effects 0.000 description 1
238000005886 esterification reaction Methods 0.000 description 1
229940031098 ethanolamine Drugs 0.000 description 1
PQJJJMRNHATNKG-UHFFFAOYSA-N ethyl bromoacetate Chemical compound CCOC(=O)CBr PQJJJMRNHATNKG-UHFFFAOYSA-N 0.000 description 1
229940012017 ethylenediamine Drugs 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000013613 expression plasmid Substances 0.000 description 1
239000013604 expression vector Substances 0.000 description 1
238000000855 fermentation Methods 0.000 description 1
230000004151 fermentation Effects 0.000 description 1
239000012091 fetal bovine serum Substances 0.000 description 1
239000003527 fibrinolytic agent Substances 0.000 description 1
230000003480 fibrinolytic effect Effects 0.000 description 1
210000002950 fibroblast Anatomy 0.000 description 1
239000000945 filler Substances 0.000 description 1
238000011049 filling Methods 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
239000000834 fixative Substances 0.000 description 1
239000007850 fluorescent dye Substances 0.000 description 1
238000012632 fluorescent imaging Methods 0.000 description 1
MEEWSBNOBXBASQ-UHFFFAOYSA-M fluoromethanesulfonate Chemical compound [O-]S(=O)(=O)[CH]F MEEWSBNOBXBASQ-UHFFFAOYSA-M 0.000 description 1
235000019264 food flavour enhancer Nutrition 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
238000001640 fractional crystallisation Methods 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
FBPFZTCFMRRESA-GUCUJZIJSA-N galactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-GUCUJZIJSA-N 0.000 description 1
238000003304 gavage Methods 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
238000007429 general method Methods 0.000 description 1
239000012362 glacial acetic acid Substances 0.000 description 1
239000003365 glass fiber Substances 0.000 description 1
229940050410 gluconate Drugs 0.000 description 1
229960003711 glyceryl trinitrate Drugs 0.000 description 1
230000004116 glycogenolysis Effects 0.000 description 1
210000004349 growth plate Anatomy 0.000 description 1
125000001475 halogen functional group Chemical group 0.000 description 1
210000003128 head Anatomy 0.000 description 1
208000019622 heart disease Diseases 0.000 description 1
229960002897 heparin Drugs 0.000 description 1
229920000669 heparin Polymers 0.000 description 1
231100000234 hepatic damage Toxicity 0.000 description 1
231100000753 hepatic injury Toxicity 0.000 description 1
239000008240 homogeneous mixture Substances 0.000 description 1
102000046278 human ADORA3 Human genes 0.000 description 1
IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 1
150000004678 hydrides Chemical class 0.000 description 1
229960002003 hydrochlorothiazide Drugs 0.000 description 1
XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
230000003301 hydrolyzing effect Effects 0.000 description 1
WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
238000010874 in vitro model Methods 0.000 description 1
NDDAHWYSQHTHNT-UHFFFAOYSA-N indapamide Chemical compound CC1CC2=CC=CC=C2N1NC(=O)C1=CC=C(Cl)C(S(N)(=O)=O)=C1 NDDAHWYSQHTHNT-UHFFFAOYSA-N 0.000 description 1
229960004569 indapamide Drugs 0.000 description 1
125000004537 indazol-5-yl group Chemical group N1N=CC2=CC(=CC=C12)* 0.000 description 1
125000001041 indolyl group Chemical group 0.000 description 1
230000006698 induction Effects 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
208000027866 inflammatory disease Diseases 0.000 description 1
208000014674 injury Diseases 0.000 description 1
229910052500 inorganic mineral Inorganic materials 0.000 description 1
CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
229960000367 inositol Drugs 0.000 description 1
208000020658 intracerebral hemorrhage Diseases 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
239000007928 intraperitoneal injection Substances 0.000 description 1
238000007914 intraventricular administration Methods 0.000 description 1
239000011630 iodine Substances 0.000 description 1
230000007654 ischemic lesion Effects 0.000 description 1
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
238000002955 isolation Methods 0.000 description 1
SRJOCJYGOFTFLH-UHFFFAOYSA-N isonipecotic acid Chemical compound OC(=O)C1CCNCC1 SRJOCJYGOFTFLH-UHFFFAOYSA-N 0.000 description 1
125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
125000000654 isopropylidene group Chemical group C(C)(C)=* 0.000 description 1
229960002479 isosorbide Drugs 0.000 description 1
MOYKHGMNXAOIAT-JGWLITMVSA-N isosorbide dinitrate Chemical compound [O-][N+](=O)O[C@H]1CO[C@@H]2[C@H](O[N+](=O)[O-])CO[C@@H]21 MOYKHGMNXAOIAT-JGWLITMVSA-N 0.000 description 1
229960000201 isosorbide dinitrate Drugs 0.000 description 1
210000004731 jugular vein Anatomy 0.000 description 1
239000008101 lactose Substances 0.000 description 1
239000004816 latex Substances 0.000 description 1
229920000126 latex Polymers 0.000 description 1
GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 description 1
239000004973 liquid crystal related substance Substances 0.000 description 1
239000012280 lithium aluminium hydride Substances 0.000 description 1
230000008818 liver damage Effects 0.000 description 1
208000019423 liver disease Diseases 0.000 description 1
238000011068 loading method Methods 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
239000004325 lysozyme Substances 0.000 description 1
229960000274 lysozyme Drugs 0.000 description 1
235000010335 lysozyme Nutrition 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
229940107698 malachite green Drugs 0.000 description 1
FDZZZRQASAIRJF-UHFFFAOYSA-M malachite green Chemical compound [Cl-].C1=CC(N(C)C)=CC=C1C(C=1C=CC=CC=1)=C1C=CC(=[N+](C)C)C=C1 FDZZZRQASAIRJF-UHFFFAOYSA-M 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
210000004962 mammalian cell Anatomy 0.000 description 1
239000011565 manganese chloride Substances 0.000 description 1
235000002867 manganese chloride Nutrition 0.000 description 1
229940099607 manganese chloride Drugs 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
238000001819 mass spectrum Methods 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
229960003194 meglumine Drugs 0.000 description 1
229960003134 mepindolol Drugs 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
239000002207 metabolite Substances 0.000 description 1
229940098779 methanesulfonic acid Drugs 0.000 description 1
IRCFVNHBBKIIPM-UHFFFAOYSA-N methyl 4-acetyloxy-3-azido-5-(6-chloropurin-9-yl)oxolane-2-carboxylate Chemical compound CC(=O)OC1C(N=[N+]=[N-])C(C(=O)OC)OC1N1C2=NC=NC(Cl)=C2N=C1 IRCFVNHBBKIIPM-UHFFFAOYSA-N 0.000 description 1
KQSSATDQUYCRGS-UHFFFAOYSA-N methyl glycinate Chemical compound COC(=O)CN KQSSATDQUYCRGS-UHFFFAOYSA-N 0.000 description 1
230000003278 mimic effect Effects 0.000 description 1
235000010755 mineral Nutrition 0.000 description 1
239000011707 mineral Substances 0.000 description 1
239000003607 modifier Substances 0.000 description 1
XONPDZSGENTBNJ-UHFFFAOYSA-N molecular hydrogen;sodium Chemical compound [Na].[H][H] XONPDZSGENTBNJ-UHFFFAOYSA-N 0.000 description 1
DOTMOQHOJINYBL-UHFFFAOYSA-N molecular nitrogen;molecular oxygen Chemical compound N#N.O=O DOTMOQHOJINYBL-UHFFFAOYSA-N 0.000 description 1
239000003068 molecular probe Substances 0.000 description 1
239000002808 molecular sieve Substances 0.000 description 1
229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
235000019796 monopotassium phosphate Nutrition 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
230000010016 myocardial function Effects 0.000 description 1
208000037891 myocardial injury Diseases 0.000 description 1
GZCNKQPANHRSAJ-UHFFFAOYSA-N n-[3,5-dimethyl-4-(nitromethylsulfonyl)phenyl]-2-(2-methylphenyl)acetamide Chemical compound CC1=CC=CC=C1CC(=O)NC1=CC(C)=C(S(=O)(=O)C[N+]([O-])=O)C(C)=C1 GZCNKQPANHRSAJ-UHFFFAOYSA-N 0.000 description 1
125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
229930014626 natural product Natural products 0.000 description 1
229960004927 neomycin Drugs 0.000 description 1
125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
238000011587 new zealand white rabbit Methods 0.000 description 1
229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
229960002715 nicotine Drugs 0.000 description 1
HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
229960001597 nifedipine Drugs 0.000 description 1
229960005425 nitrendipine Drugs 0.000 description 1
150000002825 nitriles Chemical class 0.000 description 1
239000001272 nitrous oxide Substances 0.000 description 1
230000009871 nonspecific binding Effects 0.000 description 1
238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
150000002894 organic compounds Chemical class 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
210000001672 ovary Anatomy 0.000 description 1
125000003585 oxepinyl group Chemical group 0.000 description 1
239000007800 oxidant agent Substances 0.000 description 1
125000004430 oxygen atom Chemical group O* 0.000 description 1
238000006213 oxygenation reaction Methods 0.000 description 1
238000012858 packaging process Methods 0.000 description 1
229910052763 palladium Inorganic materials 0.000 description 1
238000002638 palliative care Methods 0.000 description 1
239000012188 paraffin wax Substances 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
239000000312 peanut oil Substances 0.000 description 1
229940049954 penicillin Drugs 0.000 description 1
125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
238000010647 peptide synthesis reaction Methods 0.000 description 1
KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 1
239000008196 pharmacological composition Substances 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
239000002571 phosphodiesterase inhibitor Substances 0.000 description 1
108091000115 phosphomannomutase Proteins 0.000 description 1
PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
229910052698 phosphorus Inorganic materials 0.000 description 1
239000011574 phosphorus Substances 0.000 description 1
230000000865 phosphorylative effect Effects 0.000 description 1
239000003757 phosphotransferase inhibitor Substances 0.000 description 1
125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
XKJCHHZQLQNZHY-UHFFFAOYSA-N phthalimide Chemical compound C1=CC=C2C(=O)NC(=O)C2=C1 XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 description 1
230000008288 physiological mechanism Effects 0.000 description 1
IWELDVXSEVIIGI-UHFFFAOYSA-N piperazin-2-one Chemical compound O=C1CNCCN1 IWELDVXSEVIIGI-UHFFFAOYSA-N 0.000 description 1
229960001085 piretanide Drugs 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
239000000106 platelet aggregation inhibitor Substances 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229920001296 polysiloxane Polymers 0.000 description 1
229950010884 ponalrestat Drugs 0.000 description 1
210000003240 portal vein Anatomy 0.000 description 1
239000013641 positive control Substances 0.000 description 1
229910000160 potassium phosphate Inorganic materials 0.000 description 1
235000011009 potassium phosphates Nutrition 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
230000003449 preventive effect Effects 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
238000012545 processing Methods 0.000 description 1
AMMGCGVWJMRTQI-UHFFFAOYSA-N prop-1-en-2-yl carbonochloridate Chemical compound CC(=C)OC(Cl)=O AMMGCGVWJMRTQI-UHFFFAOYSA-N 0.000 description 1
239000003380 propellant Substances 0.000 description 1
235000019260 propionic acid Nutrition 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
239000008213 purified water Substances 0.000 description 1
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
230000002285 radioactive effect Effects 0.000 description 1
238000003127 radioimmunoassay Methods 0.000 description 1
239000002287 radioligand Substances 0.000 description 1
229960000213 ranolazine Drugs 0.000 description 1
208000022064 reactive hyperemia Diseases 0.000 description 1
229940044601 receptor agonist Drugs 0.000 description 1
239000000018 receptor agonist Substances 0.000 description 1
239000002464 receptor antagonist Substances 0.000 description 1
229940044551 receptor antagonist Drugs 0.000 description 1
238000002310 reflectometry Methods 0.000 description 1
229940107685 reopro Drugs 0.000 description 1
230000000979 retarding effect Effects 0.000 description 1
125000006413 ring segment Chemical group 0.000 description 1
YBCAZPLXEGKKFM-UHFFFAOYSA-K ruthenium(iii) chloride Chemical compound [Cl-].[Cl-].[Cl-].[Ru+3] YBCAZPLXEGKKFM-UHFFFAOYSA-K 0.000 description 1
210000003497 sciatic nerve Anatomy 0.000 description 1
CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 description 1
230000036303 septic shock Effects 0.000 description 1
208000013223 septicemia Diseases 0.000 description 1
239000004017 serum-free culture medium Substances 0.000 description 1
239000008159 sesame oil Substances 0.000 description 1
235000011803 sesame oil Nutrition 0.000 description 1
230000035939 shock Effects 0.000 description 1
150000004760 silicates Chemical class 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
239000012279 sodium borohydride Substances 0.000 description 1
229910000033 sodium borohydride Inorganic materials 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
239000011877 solvent mixture Substances 0.000 description 1
LXANPKRCLVQAOG-NSHDSACASA-N sorbinil Chemical compound C12=CC(F)=CC=C2OCC[C@@]21NC(=O)NC2=O LXANPKRCLVQAOG-NSHDSACASA-N 0.000 description 1
229950004311 sorbinil Drugs 0.000 description 1
125000003003 spiro group Chemical group 0.000 description 1
230000010473 stable expression Effects 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
238000003756 stirring Methods 0.000 description 1
238000003860 storage Methods 0.000 description 1
229960005322 streptomycin Drugs 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
239000013595 supernatant sample Substances 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
230000035488 systolic blood pressure Effects 0.000 description 1
239000007916 tablet composition Substances 0.000 description 1
229940095064 tartrate Drugs 0.000 description 1
DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 1
MNHMBOMZUYIUHR-UHFFFAOYSA-N tert-butyl 2-[2-(aminomethyl)-4-chlorophenoxy]acetate Chemical compound CC(C)(C)OC(=O)COC1=CC=C(Cl)C=C1CN MNHMBOMZUYIUHR-UHFFFAOYSA-N 0.000 description 1
BSADMUGZPVDELG-UHFFFAOYSA-N tert-butyl n-[5-(6-chloropurin-9-yl)-4-hydroxy-2-(methylcarbamoyl)oxolan-3-yl]carbamate Chemical compound OC1C(NC(=O)OC(C)(C)C)C(C(=O)NC)OC1N1C2=NC=NC(Cl)=C2N=C1 BSADMUGZPVDELG-UHFFFAOYSA-N 0.000 description 1
DKPKBWTVXUZRJC-UHFFFAOYSA-N tert-butyl n-[5-[6-[[5-chloro-2-[(3-methyl-1,2-oxazol-5-yl)methoxy]phenyl]methylamino]purin-9-yl]-4-hydroxy-2-(methylcarbamoyl)oxolan-3-yl]carbamate Chemical compound OC1C(NC(=O)OC(C)(C)C)C(C(=O)NC)OC1N1C2=NC=NC(NCC=3C(=CC=C(Cl)C=3)OCC=3ON=C(C)C=3)=C2N=C1 DKPKBWTVXUZRJC-UHFFFAOYSA-N 0.000 description 1
125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
125000005329 tetralinyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
125000004568 thiomorpholinyl group Chemical group 0.000 description 1
229960004072 thrombin Drugs 0.000 description 1
229960000103 thrombolytic agent Drugs 0.000 description 1
238000003354 tissue distribution assay Methods 0.000 description 1
LUBHDINQXIHVLS-UHFFFAOYSA-N tolrestat Chemical compound OC(=O)CN(C)C(=S)C1=CC=CC2=C(C(F)(F)F)C(OC)=CC=C21 LUBHDINQXIHVLS-UHFFFAOYSA-N 0.000 description 1
229960003069 tolrestat Drugs 0.000 description 1
JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 description 1
238000011200 topical administration Methods 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
239000006211 transdermal dosage form Substances 0.000 description 1
238000001890 transfection Methods 0.000 description 1
230000014616 translation Effects 0.000 description 1
ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 1
ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical class OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 1
PQDJYEQOELDLCP-UHFFFAOYSA-N trimethylsilane Chemical compound C[SiH](C)C PQDJYEQOELDLCP-UHFFFAOYSA-N 0.000 description 1
FTVLMFQEYACZNP-UHFFFAOYSA-N trimethylsilyl trifluoromethanesulfonate Chemical compound C[Si](C)(C)OS(=O)(=O)C(F)(F)F FTVLMFQEYACZNP-UHFFFAOYSA-N 0.000 description 1
229960000281 trometamol Drugs 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
238000009423 ventilation Methods 0.000 description 1
229960001722 verapamil Drugs 0.000 description 1
238000010792 warming Methods 0.000 description 1
238000005303 weighing Methods 0.000 description 1
MTZBBNMLMNBNJL-UHFFFAOYSA-N xipamide Chemical compound CC1=CC=CC(C)=C1NC(=O)C1=CC(S(N)(=O)=O)=C(Cl)C=C1O MTZBBNMLMNBNJL-UHFFFAOYSA-N 0.000 description 1
229960000537 xipamide Drugs 0.000 description 1
229950006343 zenarestat Drugs 0.000 description 1
239000011592 zinc chloride Substances 0.000 description 1
235000005074 zinc chloride Nutrition 0.000 description 1
DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/28—Oxygen atom
- C07D473/30—Oxygen atom attached in position 6, e.g. hypoxanthine
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Life Sciences & Earth Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Heart & Thoracic Surgery (AREA)
Neurology (AREA)
Cardiology (AREA)
Urology & Nephrology (AREA)
Physical Education & Sports Medicine (AREA)
Biotechnology (AREA)
Ophthalmology & Optometry (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Orthopedic Medicine & Surgery (AREA)
Pulmonology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Gastroenterology & Hepatology (AREA)
Vascular Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Saccharide Compounds (AREA)
Hydrogenated Pyridines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

SK418-2002A 1999-09-30 2000-09-22 Compounds for the treatment of ischemia SK4182002A3 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US15682899P	1999-09-30	1999-09-30
PCT/IB2000/001353 WO2001023399A1 (en)	1999-09-30	2000-09-22	Compounds for the treatment of ischemia

Publications (1)

Publication Number	Publication Date
SK4182002A3 true SK4182002A3 (en)	2003-04-01

Family

ID=22561263

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK418-2002A SK4182002A3 (en)	1999-09-30	2000-09-22	Compounds for the treatment of ischemia

Country Status (41)

Country	Link
EP (1)	EP1216257B1 (de)
JP (1)	JP2003510331A (de)
KR (1)	KR100481605B1 (de)
CN (1)	CN1374967A (de)
AP (1)	AP2002002458A0 (de)
AR (1)	AR029887A1 (de)
AT (1)	ATE312117T1 (de)
AU (1)	AU778185B2 (de)
BG (1)	BG106636A (de)
BR (1)	BR0014384A (de)
CA (1)	CA2386079A1 (de)
CO (1)	CO5180581A1 (de)
CR (1)	CR6592A (de)
CZ (1)	CZ20021020A3 (de)
DE (1)	DE60024649D1 (de)
EA (1)	EA005422B1 (de)
EC (1)	ECSP003682A (de)
EE (1)	EE200200172A (de)
GE (1)	GEP20043241B (de)
GT (1)	GT200000161A (de)
HK (1)	HK1049011A1 (de)
HR (1)	HRP20020253A2 (de)
HU (1)	HUP0202807A3 (de)
IL (1)	IL148222A0 (de)
IS (1)	IS6286A (de)
MA (1)	MA26822A1 (de)
MX (1)	MXPA02003308A (de)
MY (1)	MY133996A (de)
NO (1)	NO20021474L (de)
NZ (1)	NZ517177A (de)
OA (1)	OA12021A (de)
PA (1)	PA8503301A1 (de)
PE (1)	PE20010696A1 (de)
PL (1)	PL357371A1 (de)
SK (1)	SK4182002A3 (de)
TN (1)	TNSN00191A1 (de)
TR (1)	TR200200843T2 (de)
UA (1)	UA73525C2 (de)
WO (1)	WO2001023399A1 (de)
YU (1)	YU23102A (de)
ZA (1)	ZA200202461B (de)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6803457B1 (en)	1999-09-30	2004-10-12	Pfizer, Inc.	Compounds for the treatment of ischemia
EP1241176A1 (de) *	2001-03-16	2002-09-18	Pfizer Products Inc.	Purinderivate zur Behandlung von Ischämie
BR0213820A (pt) *	2001-11-02	2004-08-31	Aventis Pharma Inc	Composição farmacêutica que compreende um agonista de adenosina a1/a2 e um inibidor de trocador de sódio-hidrogênio
US7414036B2 (en)	2002-01-25	2008-08-19	Muscagen Limited	Compounds useful as A3 adenosine receptor agonists
CN101385738A (zh) *	2002-04-18	2009-03-18	Cv医药有限公司	包括给予A1腺苷激动剂以及β受体阻滞剂、钙通道阻滞剂、或强心苷的治疗心律失常的方法
TW200519106A (en)	2003-05-02	2005-06-16	Novartis Ag	Organic compounds
AU2004289690A1 (en) *	2003-11-10	2005-05-26	Schering Aktiengesellschaft	Benzylether amine compounds useful as CCR-5 antagonists
GB0401334D0 (en)	2004-01-21	2004-02-25	Novartis Ag	Organic compounds
US8293791B2 (en)	2004-03-24	2012-10-23	Fasgen, Llc	Method of neuroprotection by pharmacological inhibition of AMP-activated protein kinase
ES2525319T3 (es)	2004-05-07	2014-12-22	Janssen Pharmaceutica Nv	Derivados de pirrolidin-2-ona y piperidin-2-ona como inhibidores de 11-beta-hidroxiesteroide deshidrogenasa
GB0411056D0 (en)	2004-05-18	2004-06-23	Novartis Ag	Organic compounds
JP4642847B2 (ja) *	2004-07-28	2011-03-02	キャン−ファイト・バイオファーマ・リミテッド	シェーグレン症候群を含むドライアイ疾患治療用アデノシンａ３レセプターアゴニスト
EP1781331A1 (de) *	2004-08-09	2007-05-09	Université Catholique de Louvain	Verwendung von agonisten und antagonisten von beta-adrenozeptoren zur behandlung von arterienerkrankungen
EP1786774B1 (de)	2004-08-30	2009-10-14	Janssen Pharmaceutica N.V.	Derivate von tricyclischem lactam als 11-beta-hydroxysteroid-dehydrogenase-inhibitoren
UA87328C2 (en) *	2004-08-30	2009-07-10	Янссен Фармацевтика Н.В.	N-2 adamantanyl-2-phenoxy-acetamide derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors
DE602005017159D1 (de)	2004-08-30	2009-11-26	Janssen Pharmaceutica Nv	Oxysteroid-dehydrogenase-inhibitoren
GB0424284D0 (en)	2004-11-02	2004-12-01	Novartis Ag	Organic compounds
GB0426164D0 (en)	2004-11-29	2004-12-29	Novartis Ag	Organic compounds
GB0510390D0 (en)	2005-05-20	2005-06-29	Novartis Ag	Organic compounds
KR20080049113A (ko)	2005-10-21	2008-06-03	노파르티스 아게	Ｉｌ-13에 대항한 인간 항체 및 치료적 용도
GB0601951D0 (en)	2006-01-31	2006-03-15	Novartis Ag	Organic compounds
KR20090073121A (ko)	2006-09-29	2009-07-02	노파르티스 아게	Ｐｉ3ｋ 지질 키나제 억제제로서의 피라졸로피리미딘
BRPI0718266A2 (pt)	2006-10-30	2014-01-07	Novartis Ag	Compostos heterocíclicos como agentes anti-inflamatórios.
PT2231642E (pt)	2008-01-11	2014-03-12	Novartis Ag	Pirimidinas como inibidores de quinase
US20110281917A1 (en)	2009-01-29	2011-11-17	Darrin Stuart	Substituted Benzimidazoles for the Treatment of Astrocytomas
EP2456419B1 (de)	2009-07-21	2016-11-23	Oradin Pharmaceutical Ltd.	A3 adenosine rezeptor liganden zur modulation der pigmentierung
US8389526B2 (en)	2009-08-07	2013-03-05	Novartis Ag	3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
WO2011018454A1 (en)	2009-08-12	2011-02-17	Novartis Ag	Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation
IN2012DN01961A (de)	2009-08-17	2015-08-21	Intellikine Llc
MX2012002179A (es)	2009-08-20	2012-03-16	Novartis Ag	Compuestos heterociclicos de oxima.
WO2012034095A1 (en)	2010-09-09	2012-03-15	Irm Llc	Compounds and compositions as trk inhibitors
UY33597A (es)	2010-09-09	2012-04-30	Irm Llc	Compuestos y composiciones como inhibidores de la trk
WO2012107500A1 (en)	2011-02-10	2012-08-16	Novartis Ag	[1, 2, 4] triazolo [4, 3 -b] pyridazine compounds as inhibitors of the c-met tyrosine kinase
WO2012116237A2 (en)	2011-02-23	2012-08-30	Intellikine, Llc	Heterocyclic compounds and uses thereof
WO2012116217A1 (en)	2011-02-25	2012-08-30	Irm Llc	Compounds and compositions as trk inhibitors
US9062045B2 (en)	2011-09-15	2015-06-23	Novartis Ag	Triazolopyridine compounds
WO2013078440A2 (en)	2011-11-23	2013-05-30	Intellikine, Llc	Enhanced treatment regimens using mtor inhibitors
MX371119B (es)	2012-04-03	2020-01-17	Novartis Ag	Productos de combinacion con los inhibidores de cinasa de tirosina y su uso.
ES2699646T3 (es)	2012-05-08	2019-02-12	Aeromics Inc	Compuestos para uso en el tratamiento de enfermedades mediadas por acuaporina
RU2559776C2 (ru) *	2012-08-20	2015-08-10	Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт фармакологии имени В.В. Закусова"	Фармацевтические композиции для лечения цереброваскулярных расстройств и способы их изготовления
WO2014151147A1 (en)	2013-03-15	2014-09-25	Intellikine, Llc	Combination of kinase inhibitors and uses thereof
HK1224228A1 (zh) *	2013-11-06	2017-08-18	Aeromics, Inc.	新型制剂
TW201605450A (zh)	2013-12-03	2016-02-16	諾華公司	Ｍｄｍ２抑制劑與ＢＲＡＦ抑制劑之組合及其用途
RU2611339C2 (ru) *	2014-02-17	2017-02-21	Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт фармакологии имени В.В. Закусова"	Фармацевтические композиции с пролонгированным высвобождением для лечения цереброваскулярных расстройств
WO2016011658A1 (en)	2014-07-25	2016-01-28	Novartis Ag	Combination therapy
MX373272B (es)	2014-07-31	2020-04-16	Novartis Ag	Terapia de combinacion.
RU2582961C1 (ru) *	2015-03-04	2016-04-27	Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт фармакологии имени В.В. Закусова"	Фармацевтические композиции в жидких лекарственных формах для лечения цереброваскулярных расстройств и способы их изготовления
EP3801069A4 (de)	2018-06-01	2022-03-16	Cornell University	Kombinationstherapie für eine pi3k-assoziierte erkrankung oder störung
RU2712150C1 (ru) *	2019-08-22	2020-01-24	Общество с ограниченной ответственностью "ЦЕНТР ТРАНСФЕРА БИОТЕХНОЛОГИЙ ОКА-Биотех"	ПРИМЕНЕНИЕ ТЕТРААЦЕТИЛИРОВАННОГО 5-АМИНО-4-КАРБАМОИЛИМИДАЗОЛИЛ-1-β-D-РИБОФУРАНОЗИДА В КАЧЕСТВЕ ИНГИБИТОРА ПРОТЕИНКИНАЗЫ Cδ
TW202140550A (zh)	2020-01-29	2021-11-01	瑞士商諾華公司	使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK62692D0 (de) *	1992-05-14	1992-05-14	Novo Nordisk As
TW336938B (en) *	1992-05-21	1998-07-21	Pfizer	Calcium channel blocking polypeptides from filistata hibernalis
ATE206432T1 (de) *	1993-07-13	2001-10-15	Nasa	A3 -adenosin -rezeptor agonisten

2000
- 2000-09-05 CO CO00066880A patent/CO5180581A1/es not_active Application Discontinuation
- 2000-09-22 KR KR10-2002-7004177A patent/KR100481605B1/ko not_active Expired - Fee Related
- 2000-09-22 CA CA002386079A patent/CA2386079A1/en not_active Abandoned
- 2000-09-22 YU YU23102A patent/YU23102A/sh unknown
- 2000-09-22 MX MXPA02003308A patent/MXPA02003308A/es unknown
- 2000-09-22 HK HK03101216.3A patent/HK1049011A1/zh unknown
- 2000-09-22 UA UA2002032515A patent/UA73525C2/uk unknown
- 2000-09-22 EE EEP200200172A patent/EE200200172A/xx unknown
- 2000-09-22 DE DE60024649T patent/DE60024649D1/de not_active Expired - Lifetime
- 2000-09-22 AP APAP/P/2002/002458A patent/AP2002002458A0/en unknown
- 2000-09-22 HR HR20020253A patent/HRP20020253A2/xx not_active Application Discontinuation
- 2000-09-22 GE GEAP20006392A patent/GEP20043241B/en unknown
- 2000-09-22 CZ CZ20021020A patent/CZ20021020A3/cs unknown
- 2000-09-22 CN CN00813154A patent/CN1374967A/zh active Pending
- 2000-09-22 HU HU0202807A patent/HUP0202807A3/hu unknown
- 2000-09-22 BR BR0014384-7A patent/BR0014384A/pt not_active IP Right Cessation
- 2000-09-22 AU AU70352/00A patent/AU778185B2/en not_active Ceased
- 2000-09-22 JP JP2001526549A patent/JP2003510331A/ja active Pending
- 2000-09-22 SK SK418-2002A patent/SK4182002A3/sk unknown
- 2000-09-22 TR TR2002/00843T patent/TR200200843T2/xx unknown
- 2000-09-22 EP EP00958949A patent/EP1216257B1/de not_active Expired - Lifetime
- 2000-09-22 AT AT00958949T patent/ATE312117T1/de not_active IP Right Cessation
- 2000-09-22 OA OA1200200072A patent/OA12021A/en unknown
- 2000-09-22 PL PL00357371A patent/PL357371A1/xx not_active Application Discontinuation
- 2000-09-22 NZ NZ517177A patent/NZ517177A/en unknown
- 2000-09-22 EA EA200200316A patent/EA005422B1/ru not_active IP Right Cessation
- 2000-09-22 WO PCT/IB2000/001353 patent/WO2001023399A1/en not_active Ceased
- 2000-09-25 PA PA20008503301A patent/PA8503301A1/es unknown
- 2000-09-27 PE PE2000001021A patent/PE20010696A1/es not_active Application Discontinuation
- 2000-09-28 AR ARP000105125A patent/AR029887A1/es unknown
- 2000-09-28 MY MYPI20004553 patent/MY133996A/en unknown
- 2000-09-28 GT GT200000161A patent/GT200000161A/es unknown
- 2000-09-28 EC EC2000003682A patent/ECSP003682A/es unknown
- 2000-09-29 TN TNTNSN00191A patent/TNSN00191A1/fr unknown
- 2000-09-29 IL IL14822200A patent/IL148222A0/xx unknown
2002
- 2002-02-18 CR CR6592A patent/CR6592A/es not_active Application Discontinuation
- 2002-02-26 IS IS6286A patent/IS6286A/is unknown
- 2002-03-15 MA MA26557A patent/MA26822A1/fr unknown
- 2002-03-25 NO NO20021474A patent/NO20021474L/no unknown
- 2002-03-27 ZA ZA200202461A patent/ZA200202461B/xx unknown
- 2002-04-23 BG BG106636A patent/BG106636A/bg unknown

Also Published As

Publication number	Publication date
DE60024649D1 (de)	2006-01-12
CN1374967A (zh)	2002-10-16
HK1049011A1 (zh)	2003-04-25
KR100481605B1 (ko)	2005-04-08
ZA200202461B (en)	2003-05-28
TNSN00191A1 (fr)	2005-11-10
GT200000161A (es)	2002-03-22
EA200200316A1 (ru)	2002-08-29
AU7035200A (en)	2001-04-30
CZ20021020A3 (cs)	2003-04-16
BR0014384A (pt)	2002-07-02
GEP20043241B (en)	2004-05-25
OA12021A (en)	2006-04-19
PE20010696A1 (es)	2001-07-05
PL357371A1 (en)	2004-07-26
KR20020034206A (ko)	2002-05-08
CA2386079A1 (en)	2001-04-05
IL148222A0 (en)	2002-09-12
MY133996A (en)	2007-11-30
AR029887A1 (es)	2003-07-23
BG106636A (bg)	2003-01-31
MA26822A1 (fr)	2004-12-20
WO2001023399A1 (en)	2001-04-05
CO5180581A1 (es)	2002-07-30
HUP0202807A2 (hu)	2002-12-28
EP1216257B1 (de)	2005-12-07
CR6592A (es)	2004-02-23
JP2003510331A (ja)	2003-03-18
NO20021474L (no)	2002-05-22
ATE312117T1 (de)	2005-12-15
AP2002002458A0 (en)	2002-06-30
ECSP003682A (es)	2002-04-23
TR200200843T2 (tr)	2002-07-22
EP1216257A1 (de)	2002-06-26
PA8503301A1 (es)	2003-06-30
IS6286A (is)	2002-02-26
YU23102A (sh)	2006-01-16
EA005422B1 (ru)	2005-02-24
MXPA02003308A (es)	2002-10-04
NZ517177A (en)	2003-10-31
NO20021474D0 (no)	2002-03-25
EE200200172A (et)	2003-06-16
HUP0202807A3 (en)	2005-02-28
HRP20020253A2 (en)	2004-04-30
AU778185B2 (en)	2004-11-18
UA73525C2 (en)	2005-08-15

Publication	Publication Date	Title
SK4182002A3 (en)	2003-04-01	Compounds for the treatment of ischemia
EP3345907B1 (de)	2020-04-22	Pyrazolo[3,4-d]pyrimidin-verbindungen oder salze davon
US6803457B1 (en)	2004-10-12	Compounds for the treatment of ischemia
US20250074897A1 (en)	2025-03-06	Pyridazinones as parp7 inhibitors
US20030055021A1 (en)	2003-03-20	Compounds for the treatment of ischemia
US20240376126A1 (en)	2024-11-14	Prmt5 inhibitor and the use thereof
WO2004022536A1 (en)	2004-03-18	New heterocyclic amide compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them
BG66141B1 (bg)	2011-07-29	Бета - карболинови производни като инхибитори на фосфодиестераза
TWI605048B (zh)	2017-11-11	Novel pyrrolopyrimidine compounds or salts thereof, and pharmaceutical compositions containing the same, in particular, prophylactic and / or therapeutic agents for tumors and the like based on the inhibition of NAE
HK1203926A1 (en)	2015-11-06	Benzamide derivative
CN120752227A (zh)	2025-10-03	α，β-不饱和酰胺类化合物及其应用
WO2003035066A1 (en)	2003-05-01	2-aminoquinolone derivatives for use as impdh inhibitors
CN118696034A (zh)	2024-09-24	作为rad51抑制剂的新型双环化合物
CN116804004A (zh)	2023-09-26	作为dhodh抑制剂的化合物